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Interrogating Raf-1 Kinase Inhibitor Protein (RKIP) as a Novel Therapeutic Target for
Modulating Inflammatory Responses
Kyle T. Wright, M.D., Ph.D.
University of Connecticut, 2016
The studies presented here were designed to test if Raf-1 kinase inhibitor protein (RKIP) plays a
functionally significant role in immunity, and to interrogate its possibility of providing a novel
therapeutic target for modulating inflammatory responses. Based on previous studies from other
laboratories that attributed negative regulatory functions to RKIP in the context of MAPK and
NF-κB signaling in cell lines, we tested the hypothesis that its function was to suppress the
production of pro-inflammatory cytokines, proliferation, and cell survival. However, after
extensive investigation, our data clearly demonstrate that RKIP is actually necessary for the
production of certain cytokines, namely Type-I and Type-II interferons, but had less robust
effects on cell survivability and proliferation. Specifically, this work shows that RKIP is
integrated in the signaling pathway downstream of TCR triggering in CD8+ T cells and TLR
ligation in APCs. Finally, these studies highlight RKIP as a druggable protein, and through its
targeted inhibition, cytokine responses can be significantly diminished. Thus, this provides
elementary rationale for its potential clinical applicability in therapeutic interventions for
inflammatory diseases, especially those associated with dysregulated IFN responses. Through
this current work, we have provided a solid foundation for future studies that seek to investigate
further the molecular mechanisms of RKIP function within the immune system, as well as its
advancement into clinically relevant inflammatory disease models.
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CHAPTER 1

INFLAMMATION IN HEALTH AND DISEASE:
HOW UNDERSTANDING DIFFERENT INFLAMMOMES MAY LEAD TO
ENHANCED THERAPUETIC INNOVATION AND CLINICAL IMPLEMENTATION
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I. INTRODUCTION
Inflammation, to use a timeworn axiom, is a double-edged sword. Under normal physiological
circumstances, it operates as the most significant defense system that the human body has
developed to ward off incursion of foreign pathogens (1); however, if inappropriately directed or
poorly regulated, it can lead to significant morbidity and mortality (2). It is truly a unique
circumstance within physiology that one of the greatest assets for developing Darwinian fitness
(3), and certainly important for survival and propagation of many species, can abruptly become
one of the most substantial agents for tissue dysfunction and disease development.
Although the mechanisms by which inflammation develops have gained significant complexity
and efficiency over evolutionary time, there are still only but a handful of molecular signaling
pathways and professional immune cell types that drive the entire effective output of
inflammatory processes (4). Nevertheless, inflammation as a term in its clinical sense, and
certainly as it is portrayed to the general public, has been, until recently, used too broadly. This is
most likely responsible for the stagnation in therapeutic options for patients suffering from
“inflammatory” diseases until the advent of cytokine-specific biologicals in the 1990 (5, 6). In
reality, inflammation can vary depending on a myriad of factors including the following: 1) the
initiating stimulus or trigger (e.g. pathogenic infection, cell injury, molecular mimicry, or
inappropriate responses to a self and innocuous antigens), 2) the cell types, receptors, and
signaling pathways involved, 3) the generation of specific effector cytokine-chemokine milieus,
4) temporality (e.g. acute vs. chronic or early vs. late phase dynamics), and 5) the type of
pathology that results (e.g. systemic vs. local, tissue destruction vs. repair, etc.). The compilation
of these factors in a given mechanistic context is the inflammome (7). Humans and other higher
order mammals have, over evolutionary time, developed several discrete inflammomes in order
2

to antagonize the effects of certain pathogens (Figure 1-1). However, when these inflammomes
are induced inappropriately, they drive the development of distinctive disease causing effector
molecules that have become the basis of new interventional therapies (8). The vast majority of
biological anti-inflammatory treatments currently being researched and developed are focused on
the post hoc, direct inhibition of these downstream effectors by anti-cytokine monoclonal
antibodies or through receptor antagonists. This prevailing thought process of “end-point
treatment” has even directed a new approach to disease classification, namely a cytokine-based
disease taxonomy (9), as opposed to a traditional diagnosis based on particular tissue or organ
system dysfunction. Although this approach is a much improved way of organizing groups of
distinct diseases, it omits the processes that led to the generation of these effectors in the first
place. In this review, we will focus on delineating not only the pathogenic sequelae of these
inflammation-driving effector cytokines, but also the distinct inflammomes that lead to their
synthesis. Through this, we hope to expand the idea of a cytokine-based disease taxonomy into
an inflammome-based disease taxonomy, while directing the focus of future therapeutic
development toward those interventions that subvert a priori cytokine development, rather than
post hoc inhibition.

3

II. THE MAJOR INFLAMMOMES
A. INNATE (TNF DOMINANT)
The innate immune response is composed of different cell types that respond to diverse
endogenous or exogenous signals and mediate distinct downstream effects within minutes to
hours of activation. However, there are at least three major cytokine milieus that can be
generated based on all of these factors: tumor necrosis factor (TNF) dominant, interferon (IFN)
dominant, and inflammasome dominant. The word “dominant” is used because, in reality, all of
these responses are generated to varying degrees with any given inflammogen. For clinical
purposes, thinking about the innate response in the context of these three major divisions allows
one to clearly see that these milieus are generated by separate signaling cascades that provide
opportunity for specific therapeutic interventions.
A TNF dominant response can be generated by either pathogenic infection or trauma that results
in cell injury (10). These initiating triggers are recognized by the innate immune system through
the production of pathogen associated molecular patterns (PAMPs), or in the case of cell injury,
damage-associated molecular patterns (DAMPs) ((1, 11, 12). PAMPs, as the name implies, are
usually structural components of bacteria, viruses, or fungi that are recognized through pattern
recognition receptors (PRRs) on immune cells such as macrophages, dendritic cells, B cells, and
others (13, 14). On the other hand, DAMPs are factors found in host cells that are normally
sequestered away from immune recognition; however, in the face of cell injury or death, these
DAMPs, such as the nucleosome associated protein HMGB1, are released from cells and are
recognized by the same PRRs as PAMPs (15, 16).
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PRRs, such as the toll-like receptors (TLRs) will activate two distinct signaling pathways after
ligation, depending on which PAMP is recognized by its corresponding TLR. In the case of TNF
dominated responses, the major contributing pathway involves activation of the MyD88 adaptor
protein which is activated most strongly in the context of lipopeptides (TLR1/2 or 2/6), LPS
(TLR4), flagellin (TLR5), profilin (TLR11, 12), ribosomal RNA (TLR13), or CpG
oligodinucleotide sensing (TLR9) (14). MyD88 is responsible for coupling TLR ligation to the
activation of the pro-inflammatory transcription factor NF-κB through a complex signaling
pathway involving interleukin-1 receptor-associated kinase (IRAK) 1 and 4, TNF receptor
associated factor 6 (TRAF6), TAK1, IκB kinase (IKKα/β/γ), and finally poly-ubiquitinylation
and degradation of the inhibitor of NF-κB (IκBα) (17, 18). NF-κB function results in the
transcription of factors important for cell survival, as well as initiating a pro-inflammatory
program. Specifically, in conjunction with MAPK signaling, this leads to synthesis of the
transcription factor activator protein 1 (AP-1), which induces transcription of Tnf (19). After
TNF protein is produced, it exerts pleiotropic effects on the body including: activation of the
underlying tissue endothelium which directs other immune cells to sites of inflammation,
activation of the pro-inflammatory acute phase response from the liver (interleukin-6, C-reactive
protein, serum amyloid A, etc.), enhancement of phagocytosis and oxidative burst from
phagocytic cells, and during prolonged or systemic exposure, insulin resistance, muscle wasting,
and substantial vasodilation (10, 20, 21). Additionally, TNF signaling through its receptors can
lead to further activation of NF-κB, and subsequently more TNF production, creating a very
potent and potentially dangerous cycle of activation (22, 23).
TNF is produced in nearly every inflammatory disease; however, there are several where the
TNF predominates the response, so much so that interventional anti-TNF interventions have
5

been introduced as therapies. These include inflammatory bowel diseases (Chron’s disease and
ulcerative colitis), rheumatoid arthritis, ankylosing spondylitis, psoriasis, several vasculitides
including giant cell arteritis, and asthma that is refractory to other therapies ((6, 24, 25)).
Systemic TNF, via activation of the acute phase response, can also result in a “cytokine storm”
which leads to the initiation of systemic inflammatory response syndrome (SIRS) or sepsis for
triggers involving bacteremia, viremia, or mass tissue damage (e.g. electrocution, severe burns,
etc.) (26-28). Current anti-TNF therapies being used in the clinical setting include: anti-TNF
monoclonal antibodies (Infliximab, Adalimumab) and soluble TNF decoy receptors (29, 30).
However, many disease processes do not respond to anti-TNF therapy. In fact some, as in the
case of multiple sclerosis (31), are exacerbated with anti-TNF therapy; clearly demarcating the
importance of understanding specific inflammomes before institution of a given therapy. As antiTNF treatment was the first biologic anti-cytokine therapy to be FDA approved (in 1998)(32), it
is not surprising that this field is also the first to realize the need for a priori therapeutics,
exemplified by the recent wave of NF-κB inhibitors currently in clinical trials (33-35), as well as
TLR antagonists to prevent sepsis (36, 37).
B. INNATE (IFN DOMINANT)
The innate IFN dominant inflammome is initiated in an analogous way as to the TNF dominant
inflammome (i.e. PAMP-TLR interaction); however, the ligands recognized in these responses
are generally nucleic acids from viruses, and to a lesser extent bacteria, or even endogenous
DNA and RNA in the context of autoimmune diseases like systemic lupus erythematosus. The
signaling mechanisms of type-I IFN generation are complex but are becoming well described.
Briefly, these nucleic acid PAMPs are recognized by endosomal (TLR3, TLR7, TLR8) or
cytoplasmic (RIG-I, MDA-5, STING) sensors, and converge downstream at the level of
6

interferon regulatory factor 3 (IRF3) and IRF7 phosphorylation (38, 39). IRF3 and IRF7 act to
initiate the transcription of type-I IFNs (IFNα/β/δ/ε/ω) which, like TNF, can also enhance their
own production via a positive feed-forward loop (40). Type-I IFNs can be made by most cell
types, but plasmacytoid dendritic cells (pDCs) have been identified as professional IFNα
producing cells in response to nucleic acid PAMPs (41). The importance of pDCs in type-I IFN
production is exemplified by the fact that they have a cell-type specific alteration in their
signaling machinery that permits IFNα production directly after stimulation with TLR7 and
TLR9 ligands through a TRAF3-independent mechanism involving IKKα and IRF7 (42). Type-I
IFNs, like TNF, also have pleiotropic effects at different levels of the immune system including
activation of anti-viral response genes, the establishment of CXCR3-mediated chemokine
gradients via CXCL9 and CXCL10, and the enhancement of IFNγ from Th1 and Tc1 T cells and
NK cells (43, 44). They can also lead to STAT3 phosphorylation in macrophages and Tregs
which can induce an anti-inflammatory response via up-regulation of IL-10 and PD-L1 (45, 46).
Some diseases associated with altered type-I IFN production include SLE (47), psoriasis (48),
multiple sclerosis (therapeutic) (49), insulin-dependent diabetes mellitus (50, 51), rheumatoid
arthritis (52, 53), myasthenia gravis (54), and some hematologic malignancies (55).
Therapeutically, anti-IFN treatments for diseases like SLE and polymyositis have shown promise
is reducing symptom severity (56, 57), whereas recombinant IFNβ has been established as a
treatment for relapsing-remitting multiple sclerosis (58).
C. INNATE (INFLAMMASOME DOMINANT)
The third major inflammome driven by innate immune cells centers on activation of
inflammasomes, which are pentameric or heptameric protein complexes that serve to couple
PAMP and DAMP sensing with the proteolytic cleavage of pro-IL-1β and pro-IL-18 via caspase
7

1 (59). Several different inflammasomes exist and differ somewhat by structure, but each
contains a PRR-like protein (i.e. NOD-like receptor (NLRs) or the interferon-inducible AIM2)
which is connected to pro-caspase 1 by the adaptor protein ASC (60). These inflammasomes also
have been reported to confer resistance to different kinds of pathogens based on the PRR that is
affiliated with them. For example, the NLRP3 inflammasome responds to Staphylococcus spp.,
Listeria spp., and influenza viruses (61), the NLRC4 inflammasome is activated by intracellular
pathogens bearing flagella (62), and the AIM2 inflammasome responds to dsDNA from
Francisella tularensis, and herpes viruses (63). The exact nature of inflammasome activation and
regulation are still active areas of investigation; however, several consensuses have been
reached. First, inflammasomes usually require two signals in order to become fully responsive:
1) substrates for the inflammasome (i.e. pro-IL-1β and pro-IL-18) are generated in response to
signaling cascades downstream of other PRRs including NF-κB and Type-I IFN signaling, and 2)
the inflammasome must have a second signal that allows for the activation of pro-caspase 1 into
bioactive caspase 1, and subsequently the production of mature IL-1β and IL-18 (64). There are
many theories as to what can supply signal 2 and those include: intracellular potassium efflux
(65), extracellular ATP sensing (66), exposure to lysosomal enzymes like cathepsin B (67, 68),
and reactive oxygen species (69). Inflammasome regulation is less well understood, but factors
involved in chronic infections like prolonged IFNγ exposure can lead to inflammasome
destabilization through nitric oxidize-mediated nitrosylation (70).
The inflammasome dominant inflammome becomes medically relevant not only in response to
bacterial and viral pathogens, but also in the context of situations involving “frustrated
phagocytosis” which can result from chronic infections of Mycobacteria spp. or incidents of
sterile inflammation such as exposure to particulate antigens (71). Diseases associated with the
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inflammasome dominant inflammome include gout (uric acid crystals), asbestosis (asbestos
fibrils), berylliosis (beryllium), silicosis (silica), sarcoidosis, and amyloidosis (proteins) (72).
Each of these disease result lead to localized inflammation of the area where these particulates
are deposited which is usually the lung (beryllium, silica, asbestos), joints (uric acid), or small
blood vessels and soft tissue (amyloid). Inflammasomes are also implicated in both metabolic
disease and atherosclerosis, and may be main player in the development of insulin resistance in
type-2 diabetes mellitus (73-75). Antagonistic IL-1 therapies such as anakinra (receptor
antagonist (76)), canakinumab (anti-IL-1 mAb (77)), and rilonacept (soluble decoy receptor (78))
have proved efficacious in these types of diseases, including gout (79, 80). Many of these
therapies were initially developed for the treatment of rheumatoid arthritis; however, they have
shown limited long-term efficacy in humans (81). This illustrates that the presence of a particular
cytokine within the inflammatory milieu in a given disease, and thus an attempt to block it
therapeutically, is not sufficient in most cases to effectively decrease symptom severity.
However, a full understanding of the inflammome of a given disease can better guide clinicians
to more rational interventions.
D. ADAPTIVE (T CELL CENTRIC)
T cells are perhaps the best studied of all immune cells, namely due to their importance of
facilitating nearly every immune response in some way (82). T cells are activated after their T
cell receptor (TCR) encounters peptide antigens in the context of the major histocompatibility
complex (MHC) that have been processed and presented by APCs (83). Naïve T cells also
require a second signal in the form of co-stimulatory molecules that drive their proliferation
(clonal expansion) via the production of IL-2 (84). These are usually in the form of CD28 on the
T cell and CD80/CD86 on the APC; however, ligation of other co-stimulatory molecules such as
9

ICOS, OX40, and 4-1BB can also provide this necessary signal (20). Finally, a third signal in the
form of cytokines results in the differentiation of the activated T cell towards a specific effector
subtype which has a specific cytokine potential. Thus, the T cell centric inflammome can take on
different characteristics depending on the context in which it was induced (85). The major T cell
subsets include Th1 (driven by IL-12, IL-18, IFNα/β), Th2 (IL-4, IL-33), Th17 (TGFβ & IL-1,
IL-6, IL-21, IL-23), and T regulatory cells (TGFβ), but other, less well defined subsets also exist
including cytotoxic T helper cells, Th9, Th22, Tfh, and Tr1 (86, 87). For the purpose of this
review, we will focus on Th1, Th2, and Th17 subtypes as they have been the best studied in the
context of mediating human disease.
Th1 T cells are produced when activated in the context of IL-12, IL-18, and Type-I IFNs and
inhibited in the presence of IL-4 (88). They are defined by the major transcription factor T-bet
which is necessary for their ability to produce the effector cytokine IFNγ. Th1 T cells also
provide help to CD8+ cytotoxic T lymphocytes (CTLs) that respond to cells infected with
intracellular pathogens or altered self (cancerous cells), and kill them by production of several
soluble effector molecules including IFNγ, granzymes, granulysin, and perforin (89). CTLs can
also induce death through contact-mediated, caspase 8 dependent apoptosis by Fas-FasL (CD95CD95L) and TNF-related apoptosis-inducing ligand (TRAIL)-DR5 (90). Th1 cells have been
implicated in the pathogenesis of numerous autoimmune diseases through inappropriate
activation by self-antigens, and also the potentiation of innate immune responses through the
positive feedback effects of IFNγ (91).
Th17 T cells are produced in the context of TGFβ and other pro-inflammatory cytokines such as
IL-6, IL-1β, IL-21, IL-23, and others (92). Their differentiation to Th17 can be enhanced through
autocrine production of IL-21 (93), and also stabilized by subsequent IL-23 after the up10

regulation of IL-23R after TCR activation (94). Th17 polarization is controlled by the master
transcription factor RORγT, RORC2 in humans (95), which facilitates the production of IL-17A,
IL-17F, IL-21, and IL-23 production from Th17 T cells (96). A major known function of IL-17
is to recruit neutrophils to the sites of infection by stimulating the production of IL-8, CCL2,
CCL7, CXCL1, and CXCL5 (97). IL-17 can also promote synthesis of TNF, IL-6, and IL-1β
from epithelial cells and macrophages. Th17 cells have been implicated as pathogenic in several
mouse models of RA, IBD, psoriasis, and type-1 diabetes mellitus (98), as well as several
diseases in humans: multiple sclerosis, RA (99), SLE (100), psoriasis (101), and IBD (102).
These associations have been largely based on finding elevated IL-17 levels in either sera or
tissue biopsies from afflicted patients or direct visualization of Th17 cells within diseased tissue
biopsies (103). Several therapies exist to target the Th17 pathway including (104) (monoclonal
antibody that targets the IL-12p40 subunit shared by IL-12 and IL-23) and several anti-IL17
antibodies that are not yet FDA approved (brodalumab, ixekizumab, and secucinumab).
Ustekinumab treatment has seen some success in treating patients with psoriasis, but that success
has not translated to other Th17 implicated diseases to date (105, 106).
The final T cell subset that can define the T cell centric inflammome are Th2 T cell which
differentiate in the presence of IL-4 or IL-33 and the absence of IFNγ (107, 108). Th2 cells are
potent promoters of IL-4, IL-5, and IL-13 production and are defined by their master
transcription factor GATA3 (109). Th2 cells can also efficiently provide help to B cells through
CD40-CD40L interactions. In the presence of IL-4, B cells secrete antibodies of the IgE isotype
which are critical for protection against helminthic infection (110), but are also the main driving
force of allergic responses in humans (111). The concomitant actions of IgE, by binding its
receptor FcεRI, and Th2 cytokines potently induce granulocyte chemotaxis and degranulation of
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mast cells, eosinophil, and basophils. This degranulation releases vasoactive amines (like
histamine), serine proteases, and eicosanoids (such as prostaglandins and leukotrienes), all of
which facilitate symptoms of allergy (erythema, pruritus, bronchoconstriction) (112). Once
again, most therapies currently approved for treatment of allergic reactions are typically based on
post hoc approaches. These interventions involve blockade of histamines and leukotrienes, or
management of symptoms (e.g. bronchodilators) (113). Investigation into blocking these
responses at the level of T cell (or B cell) initiation is an area that requires attention, as too few
studies have been conducted to answer these questions.
The T cell centric inflammome can assume very diverse outcomes, and be the driving force
behind many different types of inflammatory diseases. However, because T cells undergo clonal
expansion in response to activation, they are susceptible to many of the broadly
immunosuppressive agents that aim to kill dividing cells (114, 115) . For example,
corticosteroids block the production of IL-2, and immunophilins (such as tacrolimus, and
cyclosporine) prevent calcineurin-mediated activation of NFAT, a transcription factor critical for
T cell responses (116). Also, cyclostatic drugs (e.g. methotrexate, azathioprine, mercaptopurine)
that block all cell proliferation, and are typically used in cancer therapy, are sometimes used to
prevent T cell expansion in inflammatory diseases (117). All of these therapeutic options prevent
pro-inflammatory cytokine production; however, they also suffer from lack of specificity. Future
studies aimed at improving T cell based therapeutic interventions should seek to combine the a
priori blockade of cytokine synthesis with the specificity of a biologic treatment in order to
prevent such broad immunosuppression.
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E. ADAPTIVE (B CELL CENTRIC)
The main effectors of the B cell centric inflammome are antibodies, which are generated after the
integration signals from PRR triggering, B cell receptor ligation, T cell help, and sensing of the
cytokine milieu (118). The effector functions of antibodies are well defined and include
opsonization and neutralization of pathogens, initiation of the complement cascade, and
activation of other effector cells as described above. Different antibody isotypes are generated by
activation-induced cytodine deaminase (AICD) in response to sensing the cytokine milieu by B
cells. For example, in humans the presence of IFNγ will trigger production of IgG1, IL-4 will
give IgE, while TGFβ will yield IgA (119, 120).
However, B cells can also be significant contributors to cytokine synthesis in their own right. B
cells that are primed by Th1 cells and BCR ligation will begin to produce a “Th1-like” cytokine
profile including synthesis of IFNγ and even IL-12, a cytokine not made explicitly by Th1 cells
but key for Th1 differentiation (B effector type 1 or Be-1 cells). By analogy, those primed with
Th2 cells will produce IL-2, IL-4, and IL-13 (Be-2) (121). Additionally, B cells can also produce
regulatory cytokines, such as TGFβ and IL-10, in some circumstances (Bregs). Each of the B
cell cytokine-producing subtypes have been identified in vivo (122, 123), and have documented
functional significance, especially in the context of pathogen clearance and autoimmune diseases
that result from the inappropriate production of autoantibodies like SLE (124). Nevertheless,
much remains to be studied regarding their role in cytokine-based inflammation.
F. REVERSE-PHASE IMMUNITY
Recently, more evidence is coming to light that exemplifies the bi-directionality of the immune
response, in that exposure to molecules that directly activate T cells, such as superantigens, can
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lead to T-cell mediated activation of the innate immune system (125, 126). This concept outlines
an emerging reverse-phase inflammome that relies on bystander activation of the innate immune
response through cytokines produced by the adaptive arm of the immune system, rather than
PAMP or DAMP exposure. The exact mechanism(s) by which this activation occurs is still an
area of active investigation; however, production of IL-17 by TCR γδ T cells after cooperative
activation by TCRαβ T cells has been implicated (127, 128). This novel route of innate immune
system activation will generate an inflammatory-milieu that is largely similar to those generated
by the innate inflammomes discussed previously. In cases such as Staphyloccal enterotoxin A
(SEA) mediated acute lung injury or SIRS, a physician may see a clinical picture, based on
cytokines, that heavily implicates the innate immune system as the main driving force in disease
pathogenesis; however, when trying to treat such a disease process with therapeutics such as
anti-TNF, they may encounter much difficulty because the actual pathogenic mechanism is
directed by T cells and may be better treated by agents that affect IL-17 or IL-2 production. This
illustrates that although a cytokine-based disease taxonomy allows for a better understanding of
how to treat diseases that share related milieus, it may in some cases lead clinicians to incorrect
assumptions that could be insignificant, or even deleterious to the patient.
III. RKIP: A NEW THERAPUETIC TARGET?
Raf-1 kinase inhibitor protein (RKIP) is part of the highly evolutionarily conserved
phosphatidylethanolamine-binding protein (PEBP) superfamily. This family of proteins has been
found in species from bacteria to plants to humans (129, 130), and is ubiquitously expressed, to
different degrees, in all tissues (131). RKIP (PEBP-1) was originally shown to interact with Raf1 by yeast-two hybrid screening in 1999 (132), which prevented the downstream
phosphorylation of MEK and ERK (Figure 1-2). Since this time, RKIP has been implicated as a
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regulator (both positive and negative) of important signaling pathways within cells. The
functional significance of these interactions is poorly understood, and most likely varies between
cell types. It has been shown to interact with upstream proteins involved in the NF-κB cascade,
and may facilitate the assembly or stabilization of these complexes (133). The affinity for RKIP
and its ligands can be altered based on post-translational modification events, the best example
of which is its transition from Raf-1 inhibition to GRK-2 inhibition after phosphorylation of Ser
(Thr)153. RKIP is also a positive regulator exemplified by its ability to enhance GSK-3β (134)
through the prevention of an inhibitory (Thr390) phosphorylation and by enhancing production of
the microRNA let-7 (135). RKIP has also been described as a suppressor of epithelial to
mesenchymal transition, and subsequently, invasion and metastasis of cancerous cells (136)
through a mechanism involving GSK-3β and its downstream target cyclin D1 (137).
Despite these well-defined roles for RKIP in cancer cells, its function within primary cells and
within the immune system is unknown. However, recent studies have suggested that RKIP may
be linked to immune function and potentially cytokine production. First in 2006, studies
implicated RKIP induction in successful macrophage and dendritic cell maturation in cell lines
that included the up-regulation of the scavenger receptor CD36 and decreased nuclear
localization of NF-κB (138). In 2009, Reumer and colleagues found that RKIP overexpression
in Drosophila melongaster (PEBP1 or CG18594) protected them from infection by pathogenic
bacteria through the enhanced production and secretion of immunity-related proteins (139). Also
in 2009, Ménoret et. al. demonstrated that RKIP was altered (either at the level of expression or
post-translational modification) between primed OT-I T cells that were either resting or recalled
with the cognate peptide SIINFEKL from ovalbumin (140). By blocking RKIP using the small
molecule inhibitor locostatin, the production of IFNγ and TNF was attenuated through an
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unknown mechanism. Taken together, these studies suggest that RKIP may have an
immunological function that may result in altered cytokine responses. Also, the fact that RKIP
can be inhibited exogenously allows for the possibility that it may provide a therapeutic target
for modulating a priori cytokine production.
IV. CONCLUSIONS
Inflammation is one of our body’s greatest assets as it is responsible for the defense against
harmful pathogens and facilitates removal and repair of dead or dying cells. However,
inflammation is also the pathogenic mechanism by which many diseases are manifest, leading to
significant medical and financial burdens for patients. Our ability to therapeutically intervene in
these pathophysiological processes is key to preventing undue morbidity and mortality in these
patients. Before the 1990s, the standard of care for many auto-inflammatory diseases involved
broad immunosuppression using corticosteroids or direct killing of proliferating cells, both of
which lead to significant immunosuppression and the inability to ward off potential infections.
With the advent of cytokine-specific biologics, clinicians and scientific investigators became
much more interested in specific, targeted therapies that attenuated disease, while allowing for
most of the immune response to continue unabated. This led many to consider a disease
diagnostic schema that centered on a particular cytokine milieu. This has resulted in the
development of successful therapeutic endeavors for some diseases (IBD, RA), but also to
significant failures (anti-TNF in MS, anti-IL-1 in sepsis, and anti-IL-17 in Chron’s disease) (141143). These errors were due largely in part to the analysis of post hoc cytokine production rather
than examination of the underlying inflammome that led to the generation of these cytokines in
the first place. By understanding the inner workings of the body’s different inflammomes (Figure
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1-1), even better therapies can be developed that stop altered cytokine production at the source,
rather than after the fact.
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Figure 1-1: An Inflammome-based Disease Taxonomy
A schematic representation of the cytokine networks established by the host’s major
inflammomes; the size of each circle pictorially represents the relative abundance of a given
cytokine within its respective inflammome. Human diseases associated with each inflammome
are listed in non-bold script.

18

19

Figure 1-2: RKIP: A regulator of kinase-mediated signaling cascades (A) Schematic diagram
outlining previously described RKIP function. RKIP suppresses both the Raf-MEK-ERK and
canonical NF-κB signaling cascades in the resting state; however, after stimulation RKIP is
phosphorylated at Ser(Thr)153 by protein kinase C which allows is to dimerize and lose affinity
for Raf-1 and IKK complex members while gaining affinity for GRK-2. This system allows for
the coordinated activation of multiple pathways within the cell, theoretically leading to enhanced
cytokine production, cell survival, proliferation, and locomotion. (B) A list of known RKIP
binding partners and their functions;

20

A

B

21

CHAPTER 2
MATERIALS AND METHODS
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Mice
C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). RKIP-/- mice
were engineered by the Dr. Jan Kylsik Laboratory (Department of Neuroscience, Brown
University, Providence, RI, USA) (144) and received from the laboratory of Dr. Kam Yeung
(Department of Biochemistry and Cancer Biology, University of Toledo, Toledo, OH, USA).
Once in-house, RKIP-/- mice were rederived by the Gene Targeting and Transgenic Facility
(GTTF) at the University of Connecticut Health Center (UCHC) following a standard protocol
(145). After successful rederivation, RKIP-/- were bred to C57BL/6J mice to obtain wild type
littermate controls. All mice at UCHC were housed in specific pathogen-free conditions and
handled in accordance with institutional and federal guidelines outlined by the National Institutes
of Health.
Immunizations and in vitro Stimulations
For SIRS induction, staphylococcal enterotoxin A (SEA; Toxin Tech; Sarasota, FL, USA) was
injected at 1μg per mouse diluted in 0.2ml of BSS intraperitoneally (i.p.). 48 h later a second i.p.
injection of SEA was administered and tissues harvested at 48 or 72 h after the second injection
(2°). For PAMP-TLR studies, 1μg SEA was i.p. injected followed by an i.p. injection of 10μg
lipopolysaccharide (LPS) derived from Salmonella typhimurium (Sigma-Aldrich; St. Louis, MO,
USA) 18 h after SEA and tissues were harvested 12 d after SEA administration. Doses for in
vitro stimulations with TLR ligands are as follows unless otherwise indicated: LPS 50µg/ml,
CpG-A 9µg/ml, CpG-B 9μg/ml, Poly I:C 50µg/ml, Pam3CSK4 50μg/ml (Invivogen; San Diego,
CA, USA).
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Tissue Processing
Spleens were crushed through 100 μm nylon mesh strainers (Flacon/BD Biosciences; San Jose,
CA, USA) and treated with ammonium chloride for 5 min at room temperature to lyse red blood
cells (RBCs). Pooled peripheral lymph nodes (inguinal, axillary, and brachial) were crushed
through nylon mesh strainers. Liver leukocytes were obtained as previously described (146).
Briefly, livers were perfused using a solution of PBS and sodium heparin (Sigma-Aldrich)
crushed through nylon mesh strainers, and separated by a 35% percoll gradient (Sigma-Aldrich).
Blood was obtained from the tail veins of mice before and 1.5 h after 2° SEA administration.
Blood was kept at room temperature for 30 min to allow for coagulation and then stored for 1 h
at 4°C to shrink the absolute size of the clot. Samples subsequently underwent centrifugation at
13,000 rpm at 4°C for 10 min, and the upper aqueous fraction (serum) was collected and stored
at -80°C until analysis.
Cell Purification and Sorting
For studies involving purified cell populations, splenocytes were isolated from tissue as
described above and were subjected to depletion using MicroBeads specific for CD8, CD4, and
DX5 (Miltenyi Biotec; Gladbach, Germany) and MACS LD purification columns (Miltenyi
Biotec) following the manufacturer’s protocol to obtain purified splenic APCs or subjected to
positive selection using CD8 or CD4 MicoBeads and MACS LS purification columns (Miltenyi
Biotec) to obtain purified CD8 and CD4 T cell populations. B cells were isolated using negative
selection with the B cell isolation kit (Miltenyi Biotec). Purities for bead-isolated cell
populations are routinely greater than 93% as assessed by flow cytometry.
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Cell Culturing and Flow Cytometry
For in vitro restimulations, 5 x 105 cells were cultured at 37°C and 5% CO2 in 0.2ml of complete
tumor medium (CTM) which consists of minimal essential medium (MEM) supplemented with
10% fetal bovine serum, dextrose, salts, amino acids, and antibiotics. As indicated, cells were
restimulated with 0.1μg/well SEA, 50ng/ml phorbol 12-myristate 13-acetate (PMA)
(Calbiochem; Gibbstown, NJ, USA) plus ionomycin (1μg/ml) (Invitrogen; Carlsbad, CA, USA).
For studies involving locostatin (Calbiochem), 5µM solutions diluted in CTM were used as the
effective dose with an equal volume by percent DMSO in CTM acting as the vehicle control.
These reagents were used as indicated within the corresponding figure legends. Cultures
analyzed for intracellular cytokine production by flow cytometry were stimulated in culture for
4-5 h, while cultures being utilized to assess cytokine production by ELISA were stimulated
overnight. The following mAbs were purchased from BD Biosciences: Phycoerythrin-conjugated
TNFα, IL-10, Vβ3; Biotin-conjugated CD86; Allophycocyanin-conjugated CD44, Rat IgG2a,
Rat IgG2b; FITC-conjugated Rat IgG2a, Hamster IgG; Alexa Fluor-700-conjugated CD3;
PerCP-conjugated CD4, B220, Rat IgG2a; and Pacific Blue-conjugated CD8. The following
mABs were purchased from eBioscience (Sand Diego, CA, USA): PE-conjugated CD11b,
CD25, CD80, Rat IgG1, Rat IgG2b, Hamster IgG; Biotin-conjugated Rat IgG2a; Alexa Fluor
700-conjugated MHC-II, Rat IgG2b; APC-conjugated IFNγ, B220, Rat IgG1, Rat IgG2b; FITCconjugated Foxp3, CD11c; PE-Cy7-conjugated Streptavidin; and PerCP-conjugated Rat IgG2a.
FITC-conjugated Annexin V was purchased from BD Biosciences.
Surface and intracellular staining was performed as previously outlined (147). Briefly, cells were
suspended in a wash buffer containing BSS, 3% FBS, and 0.1% sodium azide. Blockade of
nonspecific binding (Fc Block) was performed by treating cells for 10 min prior to initial
25

extracellular antibody staining with a solution containing mouse serum, human IgG, and anti-Fc
mAb 2.4G2 (148). Surface staining of approximately 1 x 106 cells/well was performed with the
aforementioned antibodies at concentrations determined by individual titration studies, ranging
from 1:50 to 1:200, for 30 min at 4°C in the dark. After incubation, cells were washed twice with
wash buffer to remove any non-bound antibody and were subsequently fixed with 2%
paraformaldehyde. For intracellular staining, the cells were additionally permeabilized with wash
buffer containing 0.25% saponin (Sigma-Aldrich) and stained with antibodies against
intracellular antigens overnight at 4°C in the dark. The following day cells were washed twice to
remove any non-bound antibody. For analysis of Foxp3 containing cells, a commercially
available staining buffer set from eBioscience was used. Flow cytometric analysis was conducted
in the UCHC flow cytometry core on a Becton Dickinson (Franklin Lakes, NJ, USA) LSR II
flow cytometer and data was analyzed using FlowJo 9.5.2 software (Tree Star; Ashland, OR,
USA).
Enzyme-linked Immunosorbent Assay (ELISA)
IFNγ, IL-10, CCL2, IL-1β, and IL-2 OptEIA ELISA kits were purchased from BD Biosciences.
ELISA kits for CCL3, CXCL10, and CCL5 were purchased from R&D Systems (Minneapolis,
MN, USA), and IFNα and IFNβ ELISA kits were purchased from PBL Interferon Source
(Piscataway, NJ, USA). All ELISAs were performed according to the manufacturer’s
instructions. Briefly, capture antibody (1:250 dilution) was coated overnight on MaxiSorp 96well plates (Thermo Scientific; Rochester, NY, USA) in coating buffer (0.1 M sodium carbonate
or 0.1M sodium phosphate). The following day, the plates were washed with PBS+0.05%
Tween-20 and blocked with PBS+10% FBS for 1 h at room temperature. Next, the plates were
washed again and incubated with supernatants from overnight cultures or from mouse sera for 2
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h at room temperature. Following, the plates were washed again and incubated with a 1:250
dilution of capture antibody plus streptavidin-HRP conjugate solution for 1 h at room
temperature. Finally, the plates were washed and incubated with substrate solution
(tetramethylbenzidine-TMB; BD Biosciences) for 30 min in the dark and stopped with 1M
phosphoric acid. Absorbance was read on a Bio-Rad iMark microplate reader (Bio-Rad;
Hercules, CA, USA) and concentrations were calculated using a standard curve line of best fit on
Microplate Manager Software (Bio-Rad). Mouse SAA ELISA kit was purchased from
Immunology Consultants Laboratory Inc. (Portland, OR, USA) and used according to the
manufacturer’s protocol. All reagents, including an antibody pre-coated plate were contained
within the kit. For assessment of serum LDH activity, sera were diluted 1:10 in a 96-well
microtiter plate (100 µl) in tandem with a 1:2 serial dilution (11600-1.33 U/ml) of native bovine
LDH standard (Cell Sciences, Canton, MA, USA). Next, 100 µl of a 1:50 mix of two
colorimetric reagents from a commercially available LDH assay kit (Clontech, Mountain View,
CA, USA) was added to the sera samples. Absorbance was measured every 10 min for 30 min at
490 nm (600 nm reference) and converted into activity units (U/ml) based on the prepared
standard curve. Because LDH can be released from disrupted RBCs, any serum samples that
showed visible signs of hemolysis were excluded from the study.
Multiplex Cytokine Analysis
Sera samples and culture supernatants were subjected to multiplex cytokine analysis using the
32-analyte Miliplex MAP kit (Millipore; Billerica, MA, USA) according to the manufacturer’s
instructions. This kit measures the following cytokines between 3.2 and 10,000 pg/ml and is
standardized by internal quality controls: G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4,
IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, CXCL10, CXCL1,
27

LIF, LIX, CCL2, M-CSF, CXCL9, CCL3, CCL4, CXCL2, CCL5, TNFα, and VEGF. The
Miliplex MAP kits were run using the Bio-Plex reader and software package (Bio-Rad).
Immunofluorescence Microscopy
Cells were isolated (~2 x 105) in PBS and affixed to 1” x 3” frosted poly-lysine coated slides
(BD Falcon) using the Cytospin 4 (Thermo Shandon; Pittsburgh, PA, USA). Cells were fixed
using 4% PFA in PBS at 4°C for 30 min. After fixation, the cells were washed three times in
PBS and then permeabilized with 0.3% Triton X-100 in PBS for 20 min at room temperature.
Next, the cells were washed again as before and then blocked using 10% naïve goat serum and
0.2% BSA in PBS for 10 min at room temperature. After blocking, the cells were incubated in
the dark overnight at 4°C in a humidified chamber using a FITC-conjugated anti-RKIP antibody
(Biorbyt; Cambridge, UK) or FITC-conjugated rabbit-anti mouse isotype control at several
concentrations. The next day, the cells were washed again as before and then mounted using
Vectasheild mounting medium (Vector Labs; Burlingame, CA, USA) containing DAPI. Slides
were visualized using the Axioplan 2 inverted fluorescence microscope (Carl Zeiss; Thornwood,
NY, USA).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from cells (~3 x 106) using the Qiagen RNeasy Mini kit (Qiagen Inc:
Valencia, CA, USA) according to the manufacturer’s instructions. Total RNA was quantified
using the NanoDrop 2000 (Thermo Scientific) spectrophotometer and then 250ng-1μg RNA was
reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad). Next, transcript levels for
IRF3 (fwd. GAGAGCCGAACGAGGTTCAG, rev. CTTCCAGGTTGACACGTCCG), IRF5
(fwd. GGTCAACGGGGAAAAGAAACT, rev. CATCCACCCCTTCAGTGTACT), IRF7 (fwd.
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GAGACTGGCTATTGGGGGAG, rev. GACCGAAATGCTTCCAGGG), TRAF3 (fwd.
CAGCCTAACCCACCCCTAAAG, rev. TCTTCCACCGTCTTCACAAAC), MDA-5 (fwd.
AGATCAACACCTGTGGTAACACC, rev. CTCTAGGGCCTCCACGAACA), TBK1 (fwd.
ACTGGTGATCTCTATGCTGTCA, rev. TTCTGGAAGTCCATACGCATTG), IKKε (fwd.
ACCACTAACTACCTGTGGCAT, rev. CCTCCCCGGATTTCTTGTTTC), IFNAR1 (fwd.
AGCCACGGAGAGTCAATGG, rev. GCTCTGACACGAAACTGTGTTTT), IFNα (fwd.
CCTGATGGTCTTGGTGGTGAT, rev. CAGTTCCTTCATCCCGACCAG), IFNβ (fwd.
AGCTCCAGCTCCAAGAAAGGACGAACAT, rev. GCCCTGTAGGTGAGGTTGATCT), and
actin (fwd. GTGGGCCGCTCTAGGCACCA, rev. CTCTTTGATGTCACGCACGA) were
determined from cDNA using the SYBR Green PCR Master Mix kit (Life Technologies; Grand
Island, NY, USA) on an ABI 7300 Real-Time PCR system (Applied Biosystems by Life
Technologies). The primer sequences were chosen from those previously validated in
PrimerBank (149) (Center for Computational and Integrative Biology, Harvard Medical School,
Cambridge, MA, USA) and were purchased from Integrated DNA Technologies (Coralville, IA,
USA). Relative fold changes between experimental and control groups were determined using
the ∆∆CT method.
RNA Sequencing and Pathway Analyses
Total RNA was isolated as before and sent to Otogenetics Crp. (Atlanta, GA, USA) for next
generation RNA-sequencing. RNA was sequenced using the HiSeq 2000 platform (Illumina inc.,
San Diego, CA, USA) at a depth of 20 million reads and analyzed using both proprietary
software capable of handling Illumina based scripts, and differential expression of FPKM
(fragments per kilobase mapped) normalized data was determined using the public domain
software: Cufflinks (UC Berkeley, Johns Hopkins University, Cal Tech). Genes of interest were
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identified by taking all genes that were found to be statistically significantly different between
experimental groups and had a relative fold change of > ±1.2. These genes of interest were next
subjected to functional pathway analysis using the IPA knowledge database (Ingenuity Systems;
Redwood City, CA, USA). IPA cross-references a user’s list of genes of interest to known
canonical signaling pathways and determines the level of enrichment of a given pathway using
the user’s gene list and fold changes. IPA then calculates a P value based on this enrichment
using Fisher’s exact test. Functional pathway analysis by IPA was also confirmed using the
Database for Annotation, Visualization and Integrated Discovery (DAVID) (Laboratory of
Immunopathogenesis and Bioinformatics, Frederick, MD, USA) (150).
Oxygen Consumption Rate (OCR) Measurements
Cells were seeded at a concentration 3x105/well in an XF96 tissue culture plate (Seahorse
Bioscience; North Billerica, MA) that had been coated with BD Cell-TAK (BD Biosciences)
overnight to improve adherence of non-adherent cells. Cells were cultured in DMEM
supplemented with 25mM glucose, 2 mM glutamine, and 1mM pyruvate. Basal, maximum and
reserve OCR was measured using the Seahorse XF 96 extracellular flux analyzed (Seahorse
Biosciences), and mitochondrial function was tested using the following reagents: oligomycin
(1μM), FCCP (2μM), rotenone (1μM) and antimycin (1μM).
Immunoblot
Whole cell lysates were generated using a solution consisting of 50mM Tris-HCl, 150mM NaCl,
5mM EDTA, 5mM EGTA, 10mM NaF, 0.5% Triton X-100, and 0.5% n-ocytl-β-Dglucopyranoside. To prevent nucleic acid contamination, the whole cell lysis buffer was
supplemented with DNAse (0.67μg/μl) and RNAse (0.33μg/μl). Additionally the phosphatase
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inhibitor sodium orthovanadate (1mM) was added to prevent loss of phosphorylated proteins.
Cell lysates were centrifuged at 25,000 x g for 10 min at 4°C. Subsequently, lysates were
resolved on 4-15% SDS-PAGE (Bio-Rad) at 100V for 60 min and the transferred to 0.2μm
nitrocellulose membranes (Bio-Rad) by semi-dry transfer at 25 V for 60 min at 4°C. Membranes
were blotted with antibodies for the following antigens: RKIP, p44/p42 ERK, ERK-1 (Cell
Signaling Technologies, Danvers, MA, USA), and Actin (Sigma-Aldrich) at 1:1000 in blocking
grade milk solution overnight at 4°C. Next, membranes were washed thrice with PBS + 0.1%
Tween-20 and blotted with goat anti-rabbit conjugated to horseradish peroxidase (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA) at 1:1000 in blocking grade milk solution at room
temperature for 2-4 h. Finally, membranes were washed again as before and visualized using
ECL chemiluminescence (GE Healthcare Biosciences; Piscataway, NJ, USA). For subcellular
fractionation studies, nuclear and cytoplasmic lysates were generated using the NE-PER reagent
kit (Thermo Scientific, Waltham, MA, USA) following the manufacturer’s instructions.
Densitometric quantification of immunoblots was conducted using GeneTools software
(Syngene; Federick, MD, USA).
PF 2D Proteomics
PF 2D lystaes were generated by lysing ~ 50 x 106 purified splenic B cells using a lysis buffer
consisting of: 7.5 M urea, 2.5 M thiourea, 12.5% glycerol, 62.5 mM Tris-HCl, 2.5% n-octyl β-Dglucopyranoside, 6.25 mM TCEP, 1.25 mM protease inhibitor mixture (Sigma-Aldrich) and
centrifuged at 25,000 × g for 1 h at 18°C. Subsequently, the buffer used for cell lysis was
exchanged using PD-10 columns (GE Healthcare Biosciences) equilibrated with PF 2D start
buffer (6M Urea, 25 mM Bis-Tris, 0.2% n-ocytl- β-D-glucopyranoside). Next, the complex
protein sample was quantified by bicinchoninic acid (BCA) Protein Assay Kit (Thermo
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Scientific; Rockford, IL, USA). Proteomic samples (2 mg) were injected into the Beckman
Coulter ProteomeLab PF 2D platform (Beckman Coulter; Brea, CA, USA) and subjected to twodimensional protein fractionation. First, the complex protein mixture was fractionated over a
ProteoSep HPCF column (Eprogen; Downers Grove, IL, USA) by isoelectric focusing with a
linear gradient between pH 8.0 and 4.0. Before first dimension fractions were purified further,
the fraction collector/injector (FC/I) apparatus was cleaned with a series of washes: 1) 100%
H2O, 2) 50% NH4OH, 3) 100% H2O, 4) 50% methanol, 5) 100% H2O, and 6) 100% start buffer.
This allows for an increased level of quality control prior to second dimension fractionation.
Next, each of these corresponding fractions was further purified over a ProteoSep HPRP column
(Eprogen) with a 0-100% acetonitrile + 0.8% trifluoroacetic acid gradient at 50°C that separates
proteins based on their hydrophobicity. Protein spectra were generated with UV light measured
at 214 nm and fractions were collected in 0.5 min intervals into 96-deep well plates and stored at
−80°C. Proteomic maps for each sample were created using ProteoView software (Beckman
Coulter) and maps between groups were analyzed for regions of similarity (signatures) and
dissimilarity (fingerprints) using the DeltaView/MultiView software package (Beckman
Coulter). It is projected that fractions of interest will be boiled at 100°C for 10 min and further
resolved by 4-15% SDS-PAGE and stained using Oriole fluorescent protein stain (Bio-Rad).
Any bands correlating to proteomic differences between groups will be excised from the gel and
sent for subsequent analysis and identification by matrix-assisted laser desorption/ionization time
of flight (MALDI-TOF) and liquid chromatography-tandem mass spectrometry (LC/MS/MS).
Statistical Analysis
Unpaired, two-tailed Student’s t tests were performed with P < 0.05 representing statistical
significance in all figures except Figure 3-1B (paired, two-tailed Student’s t test). For tests
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involving unequal standard deviations between groups, Welch’s correction was used.
Homogeneity of variance was determined by F test, with F > 0.05 as a threshold for equal
variance. F-tests were performed using Microsoft Excel 2010 software (Microsoft; Redmond,
WA, USA) and P values were determined using GraphPad Prism 6.01 (GraphPad Software;
LaJolla, CA, USA).
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CHAPTER 3

RKIP CONTRIBUTES TO IFNγ SYNTHESIS BY CD8+ T CELLS AFTER SERIAL TCR
TRIGGERING IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
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ABSTRACT
Systemic inflammatory response syndrome (SIRS) is associated with the development of severe
medical complications including progression to multiple organ dysfunction syndrome and even
death. To date, only marginal improvements in terms of therapeutic options have been
established for patients affected by SIRS. Raf kinase inhibitor protein (RKIP) is a regulator of
MAPK and NF-κB signaling cascades which are both critical for production of the
proinflammatory cytokines responsible for SIRS initiation. By testing a T cell dependent mouse
model of SIRS which utilizes staphylococcal enterotoxin A (SEA) specific for Vβ3+ T cells, we
show that RKIP is necessary for the exaggerated production of IFNγ from SIRS splenocytes.
This effect was not due to differences in T cell expansion, IL-10 production, or APC priming,
but rather a cell intrinsic defect lying downstream of the T cell receptor in SEA-specific CD8+ T
cells. Importantly, mice lacking RKIP were still able to proliferate, survive, and contribute to
cytokine production in response to PAMP-TLR mediated stimuli, despite the TCR-dependent
defects seen in our SIRS model. Finally, by blocking RKIP in wild type SIRS splenocytes, the
IFNγ response by CD8+ Vβ3+ T cells was significantly diminished. These data suggest that
RKIP may be a potential therapeutic target in SIRS by curbing effector cytokine production from
CD8+ T cells during serial TCR triggering.
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INTRODUCTION
Systemic inflammatory response syndrome (SIRS) results from the general release of large
quantities of proinflammatory cytokines into circulation. This cytokine storm has the potential to
lead to many clinical complications for patients including respiratory failure from acute
respiratory distress syndrome, gastrointestinal bleeding, anemia, deep vein thrombosis, metabolic
abnormalities, hypotension, disseminated intravascular coagulopathy, multiple organ dysfunction
syndrome, and many times death (26, 151, 152). SIRS can be prompted from many initiators
including infectious and non-infectious etiologies. These triggers range from uncontrolled
bacterial, viral, and fungal infections to pathogenic toxin exposure, organ ischemia, trauma,
autoimmune disorders, pancreatitis, hemorrhage, and substance abuse. Several studies have
shown that between 30-60% of all hospital admissions meet the clinical diagnostic criteria for
SIRS (27, 153). Even though not all patients that meet these criteria progress to severe sequelae,
SIRS remarkably carries a baseline mortality rate of ~7%, which climbs to >40% if the patient
develops symptoms of shock (27). Taken together, it is no surprise that SIRS is a both a
widespread and costly problem for health care systems nationally and globally (154).
Despite affecting a large number of patients, few therapeutics exist for SIRS. Clinical trials
attempting to inhibit inflammatory factors such as TNFα and IL-1β failed to show significant
efficacy (155, 156). A current therapeutic regimen typically involves an antimicrobial agent, if
an infection is present, medications to restore cardiac and respiratory abnormalities if needed,
and a broadly immunosuppressive corticosteroid (157, 158). Using drugs that inhibit beneficial
inflammatory responses in patients that have either concomitant infections or increased
susceptibility due to hospitalization is likely to be counterproductive.
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SIRS is very difficult to study in humans because the onset and progression is rapid, and it is
likely challenging to enroll patients that are acutely ill into clinical studies. Also, because of its
heterogeneity of origins, no unified mouse model of SIRS exists. We sought to utilize a model
system that was clinically relevant to human disease, which contained a known trigger of human
SIRS that followed the natural history of the disease in terms of its acute onset and patterns of
systemic cytokine release. One model incorporating these important facets of human SIRS is
exposure to staphylococcal enterotoxin A (SEA). SEA is produced by the human pathogen
Staphylococcus aureus, and other S. aureus enterotoxins, like toxic shock syndrome toxin-1
(TSST-1), induce rapid release of proinflammatory cytokines into the systemic circulation in
significant quantities and importantly, can cause SIRS in humans (159, 160). This robust
cytokine storm is mediated by the rapid expansion and activation of T cells that specifically bear
the Vβ3 chain of the T cell receptor (161). In addition, exposure to these superantigens has
explicitly illustrated many other aspects of SIRS pathology including the induction of acute lung
injury after vascular damage (140, 162, 163) as well as transient immunosuppression similar to
the compensatory anti-inflammatory response syndrome (CARS) seen in a number of SIRS
patients (152, 164, 165).
The major cytokine network in SIRS involves production of proinflammatory factors, such as IL6, IFNγ, and TNFα, which are dependent on the NF-κB and the MAPK signaling pathways (166,
167). It is critical to discover ways to modulate these cascades in order to control SIRS without
affecting immunocompentence. Raf kinase inhibitor protein (RKIP) negatively regulates these
pathways by binding and inhibiting the kinase activities of several important signaling factors
including Raf, MEK, ERK, TRAF6, TAK1, NIK, and IKKα/β (132, 133, 168, 169). RKIP has
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also been associated with metastatic disease in many human cancers including prostate (170) and
breast (171), but its role in the immune system is undefined.
Here we report that serial triggering of the T cell receptor with SEA models many aspects of
human SIRS and identifies IFNγ as a potential intersection between the damage associated with
SIRS and the diminished inflammation seen in CARS. This is illustrated by the fact that wild
type T cells continue to make IFNγ in SIRS even if they fail to make IL-2, and thus retain the
capability to potentiate disease. Importantly, RKIP is shown to be a critical player in these
processes because genetic loss of this protein prevents the ability of specific T cells to make
exorbitant amounts of IFNγ while only moderately affecting the anti-inflammatory cytokine,
Interleukin-10. In addition, by inhibiting RKIP using the small molecule inhibitor locostatin
(172), IFNγ production was blocked in wild type SIRS T cells. The data herein suggest that
RKIP may be a key therapeutic target for dampening the robust inflammation seen in SIRS while
preserving the CARS response.
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RESULTS
RKIP drives IFNγ production in mice undergoing SIRS
Systemic Inflammatory Response Syndrome is associated with significant morbidity and
mortality in patients, and results from the exorbitant release of inflammatory factors from
immune cells (152). To study and model human SIRS in mice, we used a regimen involving
multiple administrations of Staphylococcal enterotoxin A (SEA) that induces potent T cell
expansion by 48 h (173) and systemic proinflammatory cytokine production (Fig. 3-1A). To
verify that we had indeed prompted systemic inflammation, serum from mice 90 min after the
secondary administration of SEA was used to measure IFNγ, IL-6, SAA, and LDH. These
cytokines were chosen since they are considered prognostic markers for SIRS in human patients
(174-177). As expected, significantly increased levels of IFNγ, IL-6, SAA, and LDH were
detected in sera after SEA (Fig. 3-1B).
To determine if RKIP played a role in a SIRS response, we compared the cytokine output of
SIRS and naïve splenocytes restimulated in vitro with SEA from RKIP-/-, wild type littermates,
and C57BL/6J mice at the height of the SIRS response. Splenocytes from all mice stimulated
with SEA in vivo produced decreased levels of IL-2 when compared to naïve controls, signifying
that the T cells in these cultures were anergic or immunosuppressed similar to CARS T cells.
However, the production of the effector cytokine IFNγ was increased dramatically in wild type
mice relative to naïve, but maintained or reduced in mice lacking RKIP, suggesting that RKIP
may play a role in the optimal production of IFNγ during a SIRS response (Fig. 3-1C). Figure 31D shows that in each individual experiment the C57BL/6 splenocytes, from now on referred to
as wild type unless otherwise specified, produced substantially more IFNγ in SIRS mice versus
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naïve. The RKIP-/- SIRS splenocytes did not make increased IFNγ levels over their naïve
counterparts in this overnight culture.
To investigate the reason for reduced IFNγ production seen in Figure 3-1C/D, we phenotyped
primary and secondary lymphoid organs from naïve RKIP-/- mice and determined that there were
no underlying deficits in T cell, B cell, NK cell, or CD11b+ antigen presenting cell (APC)
populations (Fig. 3-2A), as well as important thymic subsets (Fig. 3-3A). Also, we found that
there were no deficiencies in baseline cytokine production potential of IFNγ in a multitude of
lymphoid organs (Fig. 3-2B). Next, we hypothesized that the reduced IFNγ production could be
due to a reduction in the expansion of SEA-specific (Vβ3+) T cells. No difference in either SEAspecific CD8+ or CD4+ splenic T cells by percentage or total number after SIRS induction was
detected (Fig. 3-4A/B). Based on these results we hypothesized that reduction in IFNγ
production might be T cell intrinsic.
SEA-specific CD8+ T cells are responsible for suboptimal IFNγ production in RKIP-/- mice
To test our hypothesis suggesting that if the lower levels of IFNγ were due to a defect in a
specific cell type or if it was generalized amongst all splenocytes, we harvested splenocytes from
naïve and SIRS induced RKIP-/- and wild type mice and examined IFNγ production in specific
cell populations by flow cytometry after a short-term (4 h) in vitro restimulation with SEA (Fig.
3-5A). After SIRS induction there was a marked decrease in the percentage of IFNγ producing
CD8+ Vβ3+ T cells from RKIP-/- mice compared to wild type (Fig. 3-5B). Furthermore, of the
CD8+ Vβ3+ T cells producing IFNγ, RKIP-/- cells produced lower amounts compared to wild
type cells when using mean fluorescence intensity as a measurement (Fig. 3-5C). This defect in
IFNγ production was not observed in SEA-specific CD4+ T cells (Fig. 3-5B/C), bystander T
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cells, or in splenic non-T cell populations (data not shown). Importantly, naïve T cells did not
produce IFNγ in these short-term cultures, as opposed to the overnight stimulation in Figure 1.
Perhaps this is due to the IFNγ gene locus not having sufficient time to open and translate IFNγ
mRNA into protein in 4 h. These data suggest that the suboptimal IFNγ production seen in RKIP/-

SIRS splenocytes is due to a cell intrinsic defect specifically in CD8+ Vβ3+ T cells.

Because of the reduced IFNγ production by CD8+ Vβ3+ T cells, we tested if higher levels of the
anti-inflammatory cytokine Interleukin-10 (IL-10) could explain this result, since there is a
known reciprocity between these cytokines (178). IL-10 can be induced by S. aureus
enterotoxins (179) and T regulatory cells (Tregs) proficiently synthesize this suppressive
cytokine (180), thus they were examined during SIRS in our model. Tregs from SIRS-induced
RKIP-/- mice had a decreased propensity to synthesize IL-10 during stimulation with PMA +
ionomycin when compared to wild type controls (Fig. 3-6A, left panel). This was not due to a
difference in the percentage of Tregs between groups (Fig. 3-6A, right panel) or a baseline
alteration in IL-10 production potential from naïve Tregs (Fig. 3-6B). Interestingly, when whole
splenocytes from RKIP-/- and wild type mice were restimulated with SEA and compared for IL10 induction, a slight, but not statistically significant, reduction was seen in the RKIP-/- group
(Fig. 3-6C). This implies that other cell types within the spleen have the ability to compensate, to
a degree, for the loss of IL-10 production in Tregs during SIRS associated inflammation.
SIRS CD8+ RKIP-/- T cells have an intrinsic signaling defect that lies downstream of the T
cell receptor
In order to better localize the lesion that was responsible for suboptimal IFNγ production from
RKIP-/- CD8+ Vβ3+ T cells after TCR-triggering, we wanted to determine if these cells ever had
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the potential to make IFNγ or not. Therefore, we tested RKIP-/- and wild type splenocytes after
initiation of SIRS with PMA + ionomycin restimulation as opposed to SEA. The defect in IFNγ
production by RKIP-/- SIRS CD8+ Vβ3+ T cells was no longer apparent (Fig. 3-7A, upper panel).
Furthermore, there was also no longer a difference in the release or secretion of IFNγ between
RKIP-/- and wild type splenocytes after PMA + ionomycin stimulation (Fig. 3-7B). Hence, the
signaling defect seen in RKIP-/- SIRS CD8+, but not SIRS CD4+, T cells most likely lies
downstream of TCR engagement, but upstream of the factors induced by Ca2+ influx and phorbol
esters.
Blockade of RKIP using the small molecule inhibitor locostatin greatly diminishes IFNγ
production from wild type CD8+ T cells in SIRS
In order to test the therapeutic potential of RKIP blockade in SIRS, we restimulated 48 h postSIRS induction splenocytes from wild type mice overnight with SEA or PMA + ionomycin in
the presence of locostatin or vehicle control. The optimal effective dose of locostatin was chosen
based on titration studies which elicited a dose that showed both a biological effect while leaving
the vast majority of T cells viable, even after overnight stimulation (Fig. 3-8A/B). As in RKIP-/SIRS splenocytes, inhibition of RKIP function with locostatin significantly decreased IFNγ
production after TCR re-triggering with SEA, but not after PMA + ionomycin restimulation,
suggesting once again that RKIP is playing a role downstream of the TCR (Fig. 3-7C).
Because SEA crosslinks T cells with APCs, we investigated whether the loss of IFNγ production
was due to poor APC presentation. First, we assessed expression of MHC II and the
costimulatory molecules CD80/CD86 on splenic APC populations and found no difference
between RKIP-/- and wild type littermate controls (Fig. 3-9A/B). Additionally, we isolated APCs
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and CD8+ T cells from the spleens of RKIP-/- and wild type littermate mice 48 h after SIRS
induction. We then restimulated cultures of RKIP-/- APCs and wild type (or RKIP-/-) CD8+ T
cells overnight with SEA and unlike stimulation of the intact splenocyte population (Fig. 3-1) we
observed no difference in IFNγ production (data not shown). Thus, in order to rule out any
unappreciated developmental defect that may have confounded these results, we isolated APCs
and CD8+ T cells from spleens of C57BL/6 mice 48 h after SIRS induction and treated them
separately with either locostatin or vehicle in vitro for 1 h. Cells were washed twice to remove
residual locostatin or vehicle, untreated APCs or CD8+ T cells were added, and restimulated
overnight with SEA. We observed that by pre-treating wild type CD8+ SIRS T cells with
locostatin, IFNγ production was diminished to 30% of untreated or vehicle treated controls (Fig.
3-7D). However, blocking RKIP in APCs before restimulation had little effect of IFNγ output,
once again suggesting that RKIP is playing a role at the level of the T cell and can be
therapeutically targeted to diminish IFNγ responses from CD8+ T cells during SIRS.
RKIP-/- T cells retain the ability to mount an effective response to PAMP-TLR mediated
stimuli
Because RKIP-/- SIRS CD8+ T cells have an intrinsic defect downstream of TCR triggering, we
hypothesized that RKIP-/- cells may also have difficulty with proliferation, survival, and cytokine
production during a vaccination response. In order to address this question, we replaced the
second in vivo administration of SEA in our SIRS induction model with the vaccine adjuvant
lipopolysaccharide (LPS) (Fig. 3-10A). This model mimics a standard vaccination protocol
which results in the expansion and survival of SEA-specific T cells, which become Th1-like cells
(147). We found no difference in the survival of CD4+ Vβ3+ or CD8+ Vβ3+ T cells between
RKIP-/- and wild type in terms of percentage or total number at day 12 after SEA-LPS
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immunization. This was seen in both spleen (Fig. 3-10B, Table 3-1) and liver (Fig. 3-10D, Table
3-1), as well as in pooled peripheral lymph nodes (Table 3-1). Also, there were no observable
differences in contraction of SEA-specific cells after SEA immunization alone (Table 3-1).
These data are consistent with the lack of changes in clonal expansion during the SIRS model
seen in Figure 3-4. Unexpectedly, when cells were harvested from the spleen and liver at day 12
post immunization and restimulated in vitro with SEA overnight, RKIP-/- cells now made equal
or greater amounts of IFNγ (Fig. 3-10C/E). These results were also recapitulated when cells were
restimulated with plate-bound anti-CD3 acting as the TCR-trigger instead of SEA, although a
slight reduction in IL-2 production was seen in this instance (Fig. 3-3B). Importantly these data
suggest that, although RKIP-/- CD8+ T cells have a defect in effector cytokine production during
SIRS mediated inflammation, they can still expand, survive, and contribute to effector cytokine
production in response to PAMP-TLR mediated reactions.
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DISCUSSION
SIRS is an extensive and profound burden on the U.S. healthcare system (153). One well known
cause of SIRS induction is exposure to superantigens, most famously TSST-1 enterotoxin from
Staphylococcus aureus which was directly responsible for many cases of toxic shock syndrome
in the 1980s. TSST-1 and SEA bypass canonical antigen processing and activate a large
percentage of the T cell repertoire by cross-linking β-chain variable regions, specifically Vβ3, of
the T cell receptor (TCR) to constant domains of the major histocompatibility complex on APCs
(126). T cells are critically important for mediating SIRS because they can directly release
proinflammatory factors themselves and potentiate the inflammatory and destructive effects of
innate immune cells (160). In fact IFNγ, an important T cell effector cytokine, has been shown to
be necessary for certain clinical sequelae of SIRS including acute lung injury (ALI) (163). By
utilizing a T cell-dependent model of SIRS we sought to identify proteins that could alter
cytokine production in T cells, thus lessening the inflammatory response at several different
levels. We show that RKIP represents a new, and potentially valuable, therapeutic target since its
inhibition curbs IFNγ synthesis without shutting down responses to PAMPs. From a mechanistic
perspective, we demonstrate that CD8+ T cells may be a spring for cytokine production during a
SIRS response, and have demonstrated that RKIP is coupled to continued IFNγ potential in
anergic or immunosuppressed CD8+ T cells.
However, like all animal models, SEA exposure does not recapitulate all aspects of human SIRS
perfectly. As with many inflammatory mouse models, especially ones on the C57BL/6 genetic
background, most are resistant to the typical symptomology seen in human SIRS patients (i.e.
fever, lethargy, malaise, hypovolemia, organ dysfunction, death). This may be due to
inflammatory reactions in humans and mice eliciting different genetic responses to burns,
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trauma, or endotoxemia, all of which trigger SIRS (181). Nevertheless, we feel that this model
provides at least a reasonable starting point to analyze potential molecular targets that can
modify systemic inflammatory responses.
The NF-κB and MAPK pathways are both critical for the production of proinflammatory
cytokines (166, 167) and RKIP has been previously shown to be a negative regulator of these
pathways. RKIP imparts control by interfering with the kinase activities of several signaling
factors in these cascades. Little is known regarding the in vivo effects of RKIP, especially within
the immune system. Based on the findings of these previous studies, we anticipated that mice
lacking RKIP would be more prone to exaggerated cytokine production during T cell activation,
but contrary to our hypothesis we found that RKIP was actually important for enhancing IFNγ
production in CD8+ SIRS T cells after serial triggering of the TCR with SEA (Figs. 3-1,3-5).
This is critical because SEA induces a SIRS response in mice that results in T cells that are
anergic (characterized by their failure to produce IL-2 (182), but can continue to perpetuate
inflammation due to their ability to make IFNγ in large quantities. On a molecular level we
showed that RKIP is playing a role in the signaling machinery downstream of the TCR, as
evidenced by the fact that the diminished IFNγ production from CD8+ T cells lacking RKIP was
rescued if the TCR is bypassed using PMA and ionomycin (Fig. 3-7). Interestingly, expansion of
these T cells, which is another critical process mediated by MAPK signaling, was unaltered in
our model of SIRS (Fig. 3-4). This implies that RKIP’s role within effector T cells may be more
critical for cytokine output rather than proliferation.
Currently, no choice drug exists for the treatment of SIRS. Therapy focuses on treating specific
infections, if one is present, in combination with therapies that stabilize the respiratory and
cardiovascular systems if a patient has signs of shock (157). Clinical trials centered on
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antagonizing the function of TNFα and IL-1β failed to show efficacy (28); however, our data
suggests that perhaps inhibiting the effects of IFNγ may be a better therapeutic strategy. The only
treatment to target the robust inflammation of SIRS that has shown marginally better outcomes is
the usage of low-dose steroids like hydrocortisone (183). This therapeutic approach is broadly
immunosuppressive, thereby minimizing inflammatory reactions that are advantageous to the
host, such as productive responses to vaccines or pathogens. This is critical for a patient pool that
might be afflicted with established bacterial, viral, or fungal infections. Nevertheless, this is in
contrast to patients suffering from autoimmunity where steroid-mediated suppression of the
immune system would provide beneficial effects with a diminished risk of infection compared to
SIRS. However, an ideal therapeutic for either scenario would be one which dampens the
inflammatory effects of T cells that are being chronically stimulated through the TCR (e.g.
enterotoxins in SIRS or self-antigen in autoimmunity) while leaving advantageous immune
responses, such as to a vaccine or new infection, largely intact.
RKIP may be one potential molecule that, if targeted, could possibly achieve these optimal
therapeutic goals. For example, when RKIP is absent from the immune system, or when
therapeutically targeted, effector T cells, serially triggered through their TCR, produce
significantly less IFNγ than wild type while impinging only marginally on overall IL-10
production (Fig. 3-6). In addition, when the TCR is engaged only once in vivo and adjuvanted
with TLR stimulation from LPS, splenocytes synthesize normal levels of IFNγ (Fig. 3-10). Thus,
it is possible that blockade of RKIP could diminish IFNγ production from effector T cells during
SIRS while permitting a relatively unabated response to PAMPs. Although, it remains to be
determined what would occur in a complex response where both serial TCR triggering and
PAMP-TLR mediated stimuli both exist simultaneously or what the exact role, if any, that RKIP
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plays in these responses. Finally, therapeutically targeting RKIP may provide a substantial
benefit over direct inhibition of IFNγ because it allows for the alleviation of IFNγ effects at the
level of synthesis rather than receptor binding. This may be especially important in acute SIRS
where it could be too late to impact disease outcomes once IFNγ has been produced.
Although our data suggests that a loss of RKIP leads to a T cell intrinsic defect in optimal IFNγ
production, it still does not exclude the possibility of potential T cell extrinsic effects as well. In
fact in 2006, Schuierer and colleagues showed that RKIP expression may play a role in
appropriate macrophage and dendritic cell differentiation (138). Since APCs are critical for the
activation of T cells in response to classically presented antigens, as well as superantigens, any
deficit in APC function could also impart effects onto cytokine production from T cells. We
show that RKIP is playing a role at the level of the CD8+ T cell in responses to superantigens
because inhibition of RKIP in APCs specifically had no effect on IFNγ production, but inhibition
in CD8+ T cells did (Fig. 3-7D). Also, if T cell extrinsic effects such as this were playing a large
role in our model systems, we would have expected to see little or no response in our SEA-LPS
studies, which was not the case. However, this does not explicitly rule out a potential extrinsic
defect in response to MHC-restricted peptide antigens that must undergo canonical processing
and presentation within APCs.
Another facet that makes RKIP a unique therapeutic target is that it is a druggable protein. A
small molecule inhibitor of RKIP, locostatin, is available (184). Locostatin exerts its inhibitory
effects on RKIP by alkylating a conserved histidine residue (His86) within its ligand-binding
pocket (172). Modification of this residue prevents RKIP from binding to its aforementioned
ligands, thus preventing their inhibition. In addition to abating IFNγ production from wild type
cells during SIRS (Fig. 3-7C), locostatin also potently blocks IFNγ and TNFα production upon
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triggering mouse OT-I or human antigen-specific T cells against influenza with cognate peptide
and human PBMCs treated with LPS (140). However, the specificity of this inhibitor is still
being investigated as it has several potential off target effects (184). Furthermore, the target
analyses for locostatin have largely been conducted in immortalized cell lines (185), and thus,
the exact mechanism of how it mediates its inhibitory effects within an in vivo immunological
system remains unclear. This allows significant room for improvement in developing better
target-specific inhibitors of RKIP before use in a clinical setting. Nevertheless, our new data pin
points a locostatin effect on CD8+ T cells, but not APCs, in response to the pathogenic
enterotoxin SEA (Fig. 3-7D). In sum, our data suggests that RKIP represents a potentially new
therapeutic target for reducing the effects of IFNγ from CD8+ effector T cells during the serial
TCR triggering events in SIRS.
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Figure 3-1: RKIP is necessary for optimal production of IFNγ by splenocytes during SIRS.
(A) Schematic of SIRS induction protocol. (B) Serum was isolated from C57BL/6 mice before
1° SEA and 90 min post 2° SEA treatment, and then quantified for IL-6, IFNγ, SAA, and LDH
by ELISA. Data are from 3 independent experiments, N=5-8/group. (C) Splenocytes from
C57BL/6J, WT littermate, and RKIP-/- mice were harvested 72 h after 2° SEA as depicted in
Figure 1A. 5 x 105 cells/well were stimulated overnight with 0.1μg SEA, supernatants were
collected and analyzed for IFNγ and IL-2 by ELISA. Data are from 5 independent experiments,
N=10-13/group, are expressed as a percent change from naïve splenocytes cultured and
stimulated similarly. (D) Absolute values of IFNγ for C57BL/6J and RKIP-/- from each
independent experiment in Figure 1C with Standard Error of the Mean (SEM). P values were
determined by unpaired t test between groups in Figure 3-1C/D and by paired t test in Figure 31B *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 3-2: RKIP-/- mice show no overt developmental deficits in important immunological
cell populations. (A) Cells from spleen, inguinal lymph node (ILN), axillary lymph node
(ALN),and mesenteric lymph node (MLN) were isolated from 4 week and 11 week old RKIP-/and wild type littermate mice. Cells populations were phenotyped by flow cytometric analysis.
Data are from 3 independent experiments, N=8 mice/group. Error bars represent SEM. *P<0.05.
RKIP-/- mice show no overt defects in baseline cytokine production potential. (B) Cells
from in Figure 3-2A were stimulated in vitro with PMA + Ionomycin including Brefeldin A for 4
h. After stimulation, cells were analyzed by intracellular cytokine staining. Data are from 3
independent experiments, N=8 mice/group. Error bars represent SEM. *P<0.05, **P<0.01.
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Figure 3-3: RKIP-/- mice show no loss of Thymic T cell populations. (A) Thymocytes from
Figure 3-2 mice were isolated and stained directly ex vivo for CD3, CD4, CD8, CD25, and
CD44 to determine important thymocyte populations by flow cytometric analysis. Error bars
represent SEM. P values determined by unpaired t test between groups. Plate bound anti-CD3
restimulation as a substitute TCR-trigger during SEA-LPS vaccination shows IFNγ
production is unaltered in RKIP-/- splenocytes. (B) Cells from spleen and liver in Figure 3-10
were harvested, treated, and analyzed as in Figure 3-10C and Figure 3-10E respectively. Error
bars represent SEM. P values determined by unpaired t test between groups *P<0.05.
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Figure 3-4: Reduced IFNγ production in RKIP-/- mice during SIRS is not due to reduced
expansion of SEA-specific Vβ3+ T cells. (A) Splenocytes from C57BL/6J and RKIP-/- mice
were harvested 72 h after 2° SEA as depicted in Figure 3-1A, stained directly ex vivo with
antibodies against CD3, CD4, CD8, and Vβ3, and CD3+ CD8+ or CD3+ CD4+ T cells were gated
to determine the percent Vβ3+ T cells in spleen. (B) Total cell numbers of Vβ3+ T cells from
spleen. Data in Figure 3-4A-B are from 5 independent experiments, N=15-16/group. Error bars
represent SEM and P values were determined by unpaired t test between groups.
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Figure 3-5: SEA-specific CD8+ effector T cells are responsible for suboptimal IFNγ
production in RKIP-/- mice. (A) Gating strategy for flow cytometric analysis utilized in Figure
3B-C. (B) Splenocytes were harvested as described in Figure 3-1A and restimulated in vitro with
0.1μg of SEA/well + Brefeldin A for 4 h. After restimulation, cells were analyzed by
intracellular cytokine staining for IFNγ production. Data are plots from a representative
experiment displaying median values. (C) The left panels show the mean +/- SEM of IFNγproducing T cells and (right panels) display Mean Fluorescence Intensity (MFI) of IFNγ+ T cells.
Data are from 3 independent experiments, N=8 mice/group. Error bars represent SEM and P
values were determined by unpaired t test between groups *P<0.05.
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Figure 3-6: Tregs from RKIP-/- mice during SIRS show reduced IL-10 production. (A)
Splenocytes were harvested as outline in Figure 3-1A and restimulated in vitro with PMA +
ionomycin including Brefeldin A for 4 h. After restimulation, cells were surfaced phenotyped
with antibodies against CD3, CD4, and Foxp3, stained intracellularly for IL-10 production, and
cells were then analyzed by flow cytometry. Data are from 2 independent experiments, N=56/group. (B) Splenocytes were harvested from 4 week and 11 week old naïve RKIP-/- mice or
wild type littermates (see Fig. 3-2). 5 x 105 cells/well were stimulated in vitro with PMA +
ionomycin including Brefeldin A for 4 h then surface phenotyped with antibodies specific to
CD3, CD4, and Foxp3, and stained intracellularly for IL-10 production. Data are from 3
independent experiments, N=10/group. (C) Supernatants from Figure 3-1 were analyzed for IL10 production by ELISA. Data are expressed as a percentage change from naïve splenocytes
cultured and stimulated similarly. As in Figure 3-1, data are from 5 independent experiments,
N=10-13/group. Error bars represent SEM and P values determined by unpaired t test between
groups *P<0.05.
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Figure 3-7: SEA-specific CD8+ effector T cells lacking RKIP have an intrinsic signaling
defect that lies downstream of the T cell receptor. (A) Splenocytes from Figure 3-5 were
restimulated in vitro for 4 h with PMA + ionomycin including brefeldin A and then stained with
antibodies against CD3, CD4, CD8, Vβ3, and IFNγ, followed by flow cytometric analysis. Data
are from 3 independent experiments, N=8/group. (B) Splenocytes were harvested as in Figure 37A and cultured overnight (5 x 105/well) with PMA + ionomycin. Subsequently, supernatants
were collected and analyzed for IFNγ production by ELISA. Data are from 2 independent
experiments, N=6/group. (C) 48 hr post-SIRS induction splenocytes from C57BL/6J mice were
isolated and restimulated overnight with SEA or PMA + ionomycin in the presence of medium
alone, vehicle alone (DMSO), or 5µM locostatin. The supernatants from these cultures were then
analyzed for IFNγ production by ELISA. The grey dotted line represents SEA (or PMA +
ionomycin) restimulation without locostatin or vehicle. Data are from 3 independent
experiments, N=9/group. (D) Isolated and magnetic bead purified APC and CD8+ T cell
populations from C57BL/6J mice 48 hr after SIRS induction were treated separately with either
5μM locostatin or vehicle for 1 hr. Subsequently, cells were washed twice with medium to
remove any residual locostatin or vehicle present, and then untreated APCs or CD8+ T cells (in a
1:1 ratio) were added to these cultures and restimulated overnight with 0.1μg SEA. As controls,
cultures of untreated APCs and CD8+ T cells containing locostatin or vehicle for the entire
duration were stimulated in parallel. The supernatants of these overnight cultures were then
assessed for IFNγ production by ELISA. The grey dotted line represents untreated APCs and
CD8+ T cells stimulated with SEA alone. Data are from 3 independent experiments, N=1011/group. Error bars represent SEM and P values determined by unpaired t test between groups.
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Figure 3-8: Blockade of RKIP with the small molecule inhibitor locostatin abates IFNγ
production from SEA restimulated wild type SIRS splenocytes. (A) 48 h post-SIRS induction
splenocytes from C57BL/6J mice were harvested as described in Figure 3-1A and restimulated
them overnight with SEA or PMA + ionomycin in the presence of medium alone, vehicle alone
(DMSO), or a titration of locostatin (0.5 - 50μM). The supernatants from these cultures were
then analyzed for IFNγ production by ELISA. Low dose locostatin (5μM) shows both a
biological effect on IFNγ production while leaving the bulk of T cells viable, even after
overnight stimulation. (B) Splenocytes from cultures in Figure 3-8A were stained for CD3 and
Annexin V in order to assess viability by flow cytometry.
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Figure 3-9: RKIP-/- SIRS mice have no quantitative differences in splenic APC populations
compared to wild type. (A) 48 h post-SIRS induction splenocytes were harvested from RKIP-/and wild type littermates and stained for B cells (B220) and different macrophages and dendritic
cells (CD11b, CD11c) populations. Error bars represent SEM (N=7-11, 3 independent
experiments). RKIP-/- splenic APC populations exhibit no differences in MHC-II
expression, or the costimulatory molecules CD80/86 compared to wild type. (B) APC
populations from Figure 3-9A were stained and analyzed by flow cytometry for MHC-II
(AF700), CD80 (PE), and CD86 (Biotin-PECy7) surface expression. Error bars represent SEM
(N=7-11, 3 independent experiments).
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Figure 3-10: RKIP-/- T cells can expand, survive, and contribute to cytokine production in
response to PAMP-TLR mediated stimuli. (A) Schematic representation of immunization
protocol. (B) Splenocytes were harvested at 12 d post immunization with LPS as outlined in
Figure 3-10A and stained directly ex vivo for SEA-specific (Vβ3+) T cells as outlined in Figure
3-5A. Data are from 3 independent experiments, N=11-14/group. (C) Splenocytes were
harvested as in Figure 3-10A and cultured (5 x 105/well) overnight with 0.1μg SEA. The next
day, IFNγ and IL-2 levels in supernatants were measured by ELISA. Data are from 3
independent experiments, N=11-14/group. (D) Liver leukocytes were harvested, treated, and
analyzed as in Figure 3-10B. (E) Liver leukocytes were harvested, treated, and analyzed as in
Figure 3-10C. Error bars represent SEM and P values determined by unpaired t test between
groups.
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TABLE I: Normal clonal expansion, contraction, and survival in RKIP-/- mice after SEALPS Immunization
pLN
Spleen
Liver
CD8*
CD4*
CD8
CD4
CD8
CD4
Naïve

Wild Type
RKIP

LPS

Wild Type
RKIP

SEA

-/-

Wild Type
RKIP

SEA+LPS

-/-

-/-

Wild Type
RKIP

-/-

2.61 ± 0.20

4.30 ± 0.31

2.99 ± 0.46

4.07 ± 0.18

2.44 ± 0.44

1.76 ± 0.57

2.32 ± 0.13

4.26 ± 0.12

2.80 ± 0.27

5.69 ± 0.93

2.38 ± 1.19

1.69 ± 0.46

2.70 ± 0.20

4.25 ± 0.13

3.20 ± 0.82

4.98 ± 0.72

2.17 ± 0.28

1.90 ± 0.88

2.29 ± 0.09

3.98 ± 0.60

3.27 ± 0.61

5.48 ± 0.52

2.25 ± 0.94

1.53 ± 0.13

1.14 ± 0.19

2.03 ± 0.13

2.78 ± 0.92

3.43 ± 0.25

1.59 ± 0.27

0.96 ± 0.15

1.44 ± 0.19

2.20 ± 0.17

2.03 ± 0.15

3.61 ± 0.31

1.75 ± 0.26

1.67 ± 0.29

5.36 ± 1.02

7.57 ± 1.04

9.00 ± 1.57

13.04 ± 1.86

14.18 ± 2.31

7.95 ± 1.55

5.87 ± 0.68

8.73 ± 0.78

9.13 ± 1.31

14.96 ± 1.23

12.37 ± 1.49

10.82 ± 1.55

* Percent of Vβ3+ T cells in various tissues on day 12 after no treatment, LPS, SEA, or Both
Data is a pooled analysis of all experiments in Figure 6. 3 independent experiments, N=1114/group.
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CHAPTER 4

RKIP IS INVOLVED IN DOWNSTREAM SIGNALING AFTER PATTERN
RECOGNITION RECEPTOR ENGAGEMEMENT, IMPACTING CYTOKINE
PRODUCTION
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ABSTRACT
The ability to sense pathogen-associated molecular patterns (PAMPs) through pattern
recognition receptors (PRRs) is a critical first step in our body’s defense against pathogenic
infection. Although much of the signaling mediators downstream of PRR ligation have been well
established, new molecules continue to be discovered. Previous data from our laboratory and
others suggest that one such molecule, Raf-1 kinase inhibitor protein (RKIP), which has been
proposed to interact with several important signaling proteins in pathways typically activated
after PRR ligation, may play an important role in PRR signaling events. However, RKIP’s
function within primary immune cells and specifically how RKIP effects normal PRR signaling
is currently unknown. Herein, we suggest that RKIP may play a role in PAMP sensing by PRRs,
specifically in Toll-like receptor (TLR) signaling, by forming an ordered signaling complex after
TLR ligation. The functional significance of this phenomenon is a marked loss in proinflammatory cytokine production after PAMP sensing in the absence or blockade of RKIP,
signifying that RKIP is necessary for the proper production of cytokines after TLR ligation.
These data also mark RKIP as a potential druggable target in cytokine-based therapies for
diseases related to pathogenic cytokine release.

73

INTRODUCTION
Our body’s ability to detect foreign pathogens quickly and efficiently is key in mounting an
effective immune response against them. PRRs are largely responsible for coupling PAMP
sensing to the generation of pro-inflammatory cytokines, activation and maturation of antigen
presenting cells, and subsequently effective adaptive responses of T and B cells. The importance
of PRRs and host defense has been demonstrated in both mice and humans with defective PRR
responses leading to an increased susceptibility to bacterial, viral, and fungal infections (13).
Moreover, PRR responses that are excessively robust can lead to or potentiate inflammatory
diseases including systemic inflammatory response syndrome (SIRS), inflammatory bowel
disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), atherosclerosis,
and others (36). On the other hand, because of their ability to induce potent inflammatory
responses, PRR agonists are also promising molecules for raising the adjuvanticity of certain
vaccine-based therapies (186).
The most widely studied, and best understood, family of PRRs are the TLRs, which are
responsible for sensing many structural components of pathogens including nucleic acids,
proteins, and lipoproteins. Once these patterns are sensed by TLR bearing cells, they transduce a
pro-inflammatory genetic program to the nucleus through the utilization of either the MyD88 (all
TLRs except TLR3) or TRIF (TLR3 & 4) adaptor molecules. Despite having exponentially
increased our understanding of TLR function over the past 20 years, important signaling
molecules within these pathways that modulate, potentiate, or regulate the TLR response are
continuously being discovered. In 2010, Tang and colleagues showed that RKIP interacted with
proteins downstream of MyD88 signaling in cancer cells including TRAF6, TAK-1, and IKKα/β
(169). Additionally, our laboratory has shown that RKIP blockade, using the small molecule
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inhibitor locostatin, decreased TNFα and IFNγ production from human peripheral blood
mononuclear cells (PBMCs) stimulated with the TLR4 ligand LPS (140), and that administration
of LPS helps RKIP-/- T cells overcome a deficit in IFNγ production in a mouse model of SIRS
(Fig. 3-10). These data suggest that RKIP may be a potentially important player in TLR
signaling dynamics; however, the exact nature of RKIP’s role within these responses in
unknown, especially in primary immune cells.
Through the following studies, we present data that demonstrate that RKIP is an active
participant in the early signaling events of several TLRs. Our data are consistent with the
working hypothesis that RKIP’s role is most likely to facilitate the generation and stabilization of
a membrane-associated protein complex involved with TLR signaling. The functional
importance of these interactions is demonstrated by evidence that loss of RKIP through targeteddeletion or through exogenous blockade lead to a diminished cytokine profile. Thus, this study is
the first to suggest that RKIP is not only involved in the ability of PRRs to transduce
inflammatory signals properly after PAMP sensing, but also points to RKIP as a potential target
for treating inflammatory diseases linked to inappropriate TLR responses or bolstering the
adjuvanticity of vaccines that utilize TLR agonists.
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RESULTS
Currently, exceptionally little is known regarding RKIP’s role during PAMP sensing by immune
cells. The data in Figure 3-10 show that in the context of T cell mediated inflammation, exposure
to a PAMP after TCR ligation with SEA did not result in the same defect in IFNγ production
seen after serial TCR triggering in CD8+ T cells. Additionally, our laboratory has previously
demonstrated that exposing human PBMCs to LPS during RKIP blockade with locostatin
decreases TNFα and IFNγ production from these cells (140), although this effect was very dose
dependent with low doses elevating IFNγ and higher locostatin inhibiting. Taken together, these
data suggest that RKIP may or may not play a role in TLR signaling, and that this role may be
fundamentally different than its established effect in IFNγ production from serially triggered
CD8+ T cells.
Stimulation of wild type splenocytes with LPS leads to a time and dose dependent
disappearance of RKIP protein
In order to test the hypothesis that RKIP is indeed involved in TLR signaling, we first tested the
response of bulk splenocytes from wild type C57BL/6J mice to the TLR4 agonist LPS and
measured RKIP protein levels by immunoblot over time. This heterogeneous mixture of cells,
which has been consistently characterized by many laboratories (14), contains a number of
populations capable of sensing a wide complement of PAMPs and thus provided a very
important tool for determining any generalizable effect on TLR ligation. We found that after
stimulation of these splenocytes with LPS, RKIP became very difficult to detect by immunoblot
as rapidly as 10 minutes after exposure (Fig. 4-1A/B). This effect was transient, and began
around 5 minutes after stimulation, peaked between 10-30 minutes (data not shown), and was
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nearly completely abrogated by 60-90 minutes (Fig. 4-1B and Fig. 4-2). This effect was highly
reproducible over many experiments despite being conducted with different culture medium and
varying doses of LPS. Additionally, treatment of bulk splenocytes with locostatin also impeded
the detection of RKIP by immunoblot (Fig. 4-1A) and seemed to provide an additive effect in
conjunction with LPS exposure. However, this phenomenon may be explained by masking of the
epitope that the RKIP antibody used in these studies recognizes through steric hindrance or
blockade. Unfortunately, this hypothesis cannot be tested until better site specific antibodies
corresponding to regions outside of the locostatin binding area are commercially available and
validated.
RKIP was originally characterized by its binding to, and functional inhibition of, Raf-1 kinase
which subsequently resulted in a decrease in downstream MAPK phosphorylation of MEK and
ERK (132). In order to validate that our decrease in RKIP detectability shown in Figures 4-1A/B
impinged upon its previously characterized function, we stimulated bulk splenocytes again with
a titration of LPS and measured both RKIP and phosphorylated-ERK protein levels 10 minutes
after exposure. Consistent with these previously published results, we found an inverse
relationship between RKIP protein detectability and ERK phosphorylation that was dosedependent (Fig. 4-1C and Fig. 4-1D). Taken together, these data suggest that RKIP is involved in
the early signaling events located downstream of TLR4 ligation in splenocytes, and that RKIP’s
previously characterized function (i.e. suppression of the Raf-MEK-ERK axis) may need to be
transiently prohibited in order to allow for proper ERK phosphorylation to occur during PAMP
sensing.
The inability to detect RKIP protein after PAMP stimulation is generalizable to multiple
TLR ligands
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Next, we wanted to determine if the disappearance of RKIP on immunoblot after TLR4
triggering was generalizable to multiple TLR ligands or whether it was an effect specific to LPS
sensing by splenocytes. To test this question, we stimulated bulk splenocytes with titrations of
several TLR ligands including: Pam3Cys (TLR1/2), Poly I:C (TLR3), LPS (TLR4), CpG type A
(TLR9), and CpG type B (TLR9), and then measured RKIP by immunoblot at 10 minutes, 30
minutes (data not shown), and 90 minutes after TLR ligation. These agonists were chosen in
order to stimulate both of the different signaling pathways downstream of TLRs (i.e. MyD88 and
TRIF) independently (e.g. TLR3 vs. TLR9) or cooperatively (TLR4). We found that each of the
TLR ligands tested exhibited the same phenomenon observed in Figure 4-1; however, each did
so with varying potencies and kinetics (Fig. 4-2A). Poly I:C and CpG-A seemed to have the most
profound effect on RKIP detectability, with LPS and CpG-B affecting RKIP less robustly.
Interestingly, TLR2 ligation with Pam3Cys also led to a decrease in RKIP, but the effect was
delayed until 30-90 minutes after stimulation. The stimuli also differed in the duration that RKIP
remained less detectable. CpG-A and LPS affected RKIP at 10 minutes post stimulation but by
90 minutes the effect had ceased, whereas Poly I:C and CpG-B seemed to still have an effect on
RKIP up to 90 minutes after TLR ligation (Fig. 4-1B). These data suggest that although RKIP
may be involved in the signaling machinery of all TLRs tested here, the degree to which it is
utilized, and the timing of its utilization, may vary depending on the nature of the stimulus.
Proteosomal degradation and de novo translation impart only minor contributions to the
disappearance of RKIP
Next, we wanted to better understand the molecular mechanism of RKIP’s disappearance after
PAMP sensing in splenocytes. Based on our previous findings, two hypotheses emerged as
potential possibilities to explain RKIP’s disappearance: 1) proteosomal degradation with
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subsequent de novo translation of RKIP protein and 2) sequestration of RKIP into a signaling
complex, and/or altered subcellular localization, which rendered it insoluble during lysate
generation. In order to test the former hypothesis, we cultured splenocytes again with LPS or
medium alone in the presence of the translational inhibitor cyclohexamide. Also, based on the
transient nature of LPS’s effect on RKIP detectability, we suspected that the presence of presynthesized RKIP mRNA was highly likely given that de novo transcription and subsequent
translation of new protein can take much longer than the 90 minutes it took for RKIP to reappear.
Because of this, we also repeated our stimulation in the presence of the transcriptional inhibitor
actinomycin D to determine whether or not de novo transcription was necessary for detection of
RKIP at 90 minutes post TLR ligation. We found that after stimulating splenocytes with LPS in
the presence of actinomycin D, there was no effect on the RKIP’s disappearance at 10 minutes
post TLR ligation and reappearance at 90 minutes, confirming our suspicion that de novo
transcription of RKIP was likely not involved with this phenomenon (Figs. 4-3A/C).
Additionally, stimulating in the presence of cyclohexamide only had minimal effects are
preventing the re-detectability of RKIP at 90 minutes in one of two experiments, suggesting that
de novo translation of RKIP protein also plays little to no role (Figs. 4-3A/C). Finally, we wanted
to determine if degradation via the proteasome played a role in the rapid loss of RKIP detection.
In order to test this, we repeated our LPS stimulation in splenocytes after a 10 minute pretreatment with the pan-proteasome inhibitor lactacystin. Due to the rapidity of RKIP’s
disappearance, pre-treatment was required in order to assure that the majority of cellular
proteasomes were blocked before stimulation commenced. The active β-lactone intermediate
responsible for proteosomal inhibition has been shown to peak at 10 minutes and decay shortly
thereafter with a half-life around 30 minutes (187). When comparing the amount of detectable
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RKIP at 10 minutes after TLR4 ligation between splenocytes pre-treated or not with lactacystin,
we found only a small increase in the amount of RKIP in the pre-treated group (Fig. 4-3B).
There still remains a possibility that RKIP may be degraded by a non-proteosomal mechanism,
such as cleavage via cellular caspases; however, after assessing RKIP’s primary amino-acid
sequence using the bioinformatics tool ExPASy Peptide Cutter, no cleavage sites for any nonproteosomal peptidases were found (Table II). Nevertheless, taken together these data suggest
that the transient loss of RKIP detection after PAMP sensing may be impacted by proteosomal
degradation and de novo protein synthesis.
The disappearance of RKIP protein after PAMP stimulation may be due to insoluble
complex formation or altered subcellular localization
In order to test our second hypothesis regarding the disappearance of RKIP, we first looked at
RKIP’s cellular distribution in splenocytes after LPS stimulation by immunofluorescent
microscopy. Interestingly, we observed that after TLR4 ligation with LPS, RKIP’s pattern of
staining changed drastically. Splenocytes cultured in medium alone had an RKIP staining pattern
that was diffusely spread across the cytoplasm with a small increase in intensity at the cell
membrane, but after LPS stimulation, this RKIP staining pattern became much more punctate in
nature and seemed to be localized into a very small, clustered region within each cell that was in
or near the nucleus (Fig. 4-4A). This finding gave credence to the idea that RKIP may be a
member of a distinct signaling complex that forms after TLR ligation. To look at this further, we
repeated our LPS stimulation and separated our lysates into “cytoplasmic” and “nuclear”
fractions using a commercially available kit. After TLR4 ligation, RKIP could be seen within the
“nuclear” fraction, but was absent in splenocytes that were cultured in medium alone (Fig. 4-4B).
This nuclear RKIP band was much less intense, but still present at 90 minutes post LPS
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stimulation. Also of note, the molecular weight of the nuclear RKIP band was slightly higher
than that found within the cytoplasm, suggesting that the form of RKIP found within this fraction
may very well be post-translationally modified in some way. There are numerous putative post
translational modification sites contained within RKIP that could explain this shift; however,
most of these sites still need validation (Table II). Finally, even though we were able to confirm
that our commercial subcellular fractionation kit was able to prevent cytoplasmic protein
contamination into our “nuclear” fractions (confirmed by the exclusivity of Hsp90, a purely
cytoplasmic protein, within our cytoplasmic fractions), we still cannot rule out the possibility
that RKIP may also be tethered to the cytoplasmic membrane or endoplasmic reticulum (ER)
within these punctate regions of staining seen in Figure 4-4A, given that many studies have
highlighted the problem of membrane and ER-associated protein contamination into “nuclear”
fractions in commercial kits that utilize RIPA buffer (188). Nevertheless, these data suggest that
after PAMP sensing in splenocytes, RKIP does not undergo substantial degradation, and its
disappearance on immunoblot analysis is more consistent with its re-direction into an ordered
signaling complex that becomes insoluble during our normal lysate generation, most likely due
to its tethering to insoluble material such as membrane-associated lipid rafts.
Loss of RKIP by genetic knockout or exogenous blockade leads to altered cytokine and
chemokine responses after TLR stimulation
In order to determine if loss of RKIP had any significant downstream functional effects after
TLR ligation, we stimulated bulk mesenteric lymph node (MLN) cells from RKIP-/- mice and
wild type littermates with the TLR9 ligand CpG-A overnight. The supernatants from these
cultures were then subjected to multiplex cytokine analysis that measured the output of 32
distinct cytokines and chemokines from these cells. Many cytokines were found to be lower than
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the lowest limit of assay detection in both RKIP-/- and wild type littermate bulk MLN cells after
TLR9 ligation: G-CSF, IL-1β, IL-2, IL-3, IL-4, IL-7, IL-10, IL-15, IL-17A, CCL2, LIF, M-CSF,
VEGF, and Eotaxin (data not shown). Of the cytokines and chemokines that were induced by
CpG, the vast majority were generated in much smaller quantities in RKIP-/- MLN cells
compared to wild type littermate: TNFα, GM-CSF, IL-5, IL-6, IL-9, IL-12, CXCL1, CXCL2,
CXCL5, CCL3, CCL4, and CCL5 (Fig. 4-5A). This suggests that RKIP may be necessary for
adequate production of some cytokines and chemokines following triggering of the MyD88
pathway. Also, consistent with our previous findings that SEA-LPS vaccination led to slightly
higher IFNγ output in RKIP-/- mice (Fig. 3-10C) and previous data showing that low doses of
locostatin increased IFNγ after LPS stimulation of human PBMCs (140), we also observed
increased levels of IFNγ, as well as the interferon-stimulated genes CXCL9, and CXCL10 after
CpG stimulation of RKIP-/- MLN cells (Fig. 4-5A). In order to validate the observation that loss
of RKIP results in decreased cytokine output after TLR ligation, we treated wild type
splenocytes with either LPS or CpG-A overnight in the presence of exogenous RKIP blockade
using the small molecule inhibitor locostatin and measured IL-6 and TNFα production in the
culture supernatants. Consistent with our findings in Figure 4-5A, splenocytes treated with
locostatin had markedly lower production of both cytokines measured (Fig. 4-5B), once again
suggesting that functional RKIP is necessary for appropriate cytokine production during TLR
signaling in splenocytes.
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DISCUSSION
Charles Janeway first hypothesized the existence of a group of receptors important for
recognizing foreign pathogens and providing the initiating events in host defense in Approaching
the Asymptote? Evolution and Revolution in Immunology during a Cold Spring Harbor symposia
in 1989 (189). Since that time, a voluminous literature base has been developed supporting
Janeway’s theory, and currently we understand, in moderate detail, the existence, specificity,
function, and importance of PRRs in host immunity and disease. After initially being discovered
in plants in 1995 (190), groups shortly thereafter described their function in Drosophila
melongaster (191), Mus musculus (192), and Homo sapiens (193). The first family of PRRs to be
functionally described was the Toll-like receptors, named after their homology to a known
Drosophila protein involved in embryonic polarity, Toll, initially discovered in 1985 (194).
TLRs were found to recognize a number of different structural molecules found in bacteria,
viruses, and fungi, including: LPS and lipopeptides, single and double-stranded RNA and DNA,
flagellin, a protein involved in bacterial motility, and unmethylated CpG sites in DNA.
Currently, it is known that many more families of PRRs exist in mice and humans including: Ctype lectin receptors (CLRs) which respond to glycoproteins and glycolipids, NOD-like receptors
(NLRs) which recognize structural components of peptidoglycan and are responsible for
coupling other PRRs to the inflammasome, and RIG-I-like receptors (RLRs) which respond to
intracellular nucleic acids.
Despite the immense collection of PAMPs that PRRs can recognize, the vast majority of
signaling events after PRR ligation are restricted to two well-defined pathways named for the
adapter molecule that initiates them: myeloid differentiation primary response gene 88 (MyD88)
and TIR-domain-containing adapter-inducing interferon-β (TRIF)(195). All TLRs except for
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TLR3 signal through MyD88 (196-198), while TLR3 and TLR4 can signal through TRIF (199,
200). MyD88 signaling leads to the induction of NF-κB through the canonical pathway, and
subsequently, the production of many pro-inflammatory cytokines (through AP-1), as well as costimulatory molecules important for providing “signal 2” to T cells during activation (201). On
the other hand, TRIF activation leads to a type I interferon dominated response (through IRF3/7)
which is important for anti-viral immunity (202). Despite having some differences in upstream
signaling molecules, ligation of CLRs, NLRs, and RLRs also lead to the activation of these
downstream signaling molecules. Even though the MyD88 and TRIF pathways have been well
defined, molecules that are important for proper transduction through these pathways are still
being discovered on a regular basis, as exemplified by the recent discovery of STING as an
alternative means of type I interferon generation (203).
Previously, our lab and others have suggested that RKIP may be another such molecule
important for PRR signaling. This hypothesis was based on several lines of evidence including:
the fact that RKIP binds several molecules upstream of NF-κB activation (TRAF6, IKKα/β and
TAK1; (133)), that blockade of RKIP with low dose locostatin in human PBMCs leads to
decreased TNFα production after LPS stimulation (140), and administration of LPS helps RKIP-/T cells overcome a deficit in IFNγ production (204). Nevertheless, the exact nature of RKIP’s
role in primary cells remains unknown, and provides an important area for investigation.
Through our studies, we demonstrate that RKIP is markedly affected after stimulation of bulk
splenocytes with the TLR4 ligand LPS. This is evidenced by the fact that RKIP becomes
exceedingly difficult to detect by immunoblot shortly, but transiently, after TLR ligation (Fig. 41A/B), the mechanism of which we still do not understand completely. This “disappearance”
begins as early as 5 minutes after stimulation, peaks at 10-30 minutes, and is almost completely
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resolved 60-90 min later. Importantly, this phenomenon was generalizable to stimulation through
TLRs that activate My88 alone, TRIF alone, or both together, suggesting that RKIP probably
plays a role in both pathways (Fig. 4-2), albeit with different potency and kinetics. Although, the
relative impact of RKIP on each pathway individually, and whether or not this is an effect of a
specific lesion that lessens heterologous pathway activation, requires additional study.
Interestingly, in these experiments it became clear that the RKIP inhibitor locostatin also leads to
an inability to detect RKIP using this method (Fig. 4-1C/D). This finding could be due to several
factors including epitope masking by steric hindrance of locostatin when bound within RKIP’s
ligand binding pocket, or increased proteosomal degradation when RKIP is pulled away from
potential binding partners by locostatin.
Next, we sought to better understand RKIP function after PRR triggering. Based on previous
work demonstrating the RKIP can act as a negative regulator of MAPK signaling in vitro, and
given the rapidity of RKIP’s “disappearance” seen in Figure 4-1, we hypothesized that perhaps it
was essential for RKIP to be degraded in order to provide the release of inhibition necessary for
TLR signaling to proceed. Additionally, because of the transient nature of this effect, we also
hypothesized that pre-synthesized RKIP mRNA must be present within the cell in order to
bypass de novo transcription, a process which typically requires at least several hours to generate
a biologically observable effect (205). Our data show that RKIP’s disappearance on immunoblot
is not robustly affected by pre-treatment with the pan-proteosomal inhibitor lactacystin (Fig 43B). This does not rule out the possibility of another form of protein degradation with an
endogenous peptidase; however, a bioinformatic analysis using ExPASy-peptide cutter
exemplifies that RKIP lacks putative cleavage sites for caspases 1 through 10, factor Xa,
thrombin, and granzyme B (Table II). RKIP detectability was also not robustly affected by pre85

treatment with either the transcriptional inhibitor actinomycin D or the translational inhibitor
cyclohexamide (Fig. 4-3A) after TLR ligation. Additionally, we tested if RKIP was secreted after
TLR ligation in splenocytes by immunoblotting for RKIP in the supernatants from these cultures
and found that they were devoid of detectable RKIP (data not shown). Based on these data, we
concluded that intracellular levels of RKIP were most likely staying relatively constant after
PRR triggering. Given this, we next determined that it was necessary to investigate RKIP by
utilizing immunofluorescence which would provide us the opportunity to visualize RKIP over
the time of our stimulation, and could potentially corroborate our immunoblot findings. It is
shown by immunofluorescence not only that RKIP was still observable after TLR4 ligation, but
also that the staining pattern became very punctate in nature instead of cytoplasmically diffuse
(Fig. 4-4A). This observation suggests that RKIP is more likely being recruited to a signaling
complex after stimulation, rather than being degraded and resynthesized. Because RKIP has only
been previously described as a negative signaling regulator, these data also imply a dual role for
RKIP in that it may additionally act in a positive manner to promote signal transduction, perhaps
as a scaffold protein. Furthermore, after utilizing a subcellular fractionation method in place of
traditional whole cell lysis, we were able to find RKIP within “nuclear” fractions after LPS
stimulation (Fig. 4-4B). As aforementioned, these fractions are highly contaminated by proteins
that are associated with cytoplasmic and organelle membranes, especially proteins contained in
lipid rafts. This type of signaling architecture is exceptionally common for MAPK transduction,
which recruits signaling complexes to the plasma membrane by KSR (206), endosomes via MP1
(207) and β-arrestin (208), endoplasmic reticulum by ERi1 (209), and to the golgi apparatus via
Sef (210). This is especially significant given that RKIP also contains a pleckstrin homology
domain, which is necessary for recruitment and binding to lipids (Table II). It is difficult to
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determine at this time with absolute confidence whether RKIP is located within the nucleus or in
one of these membrane-associated signaling complexes, given the fact that RKIP also has a
putative nuclear localization sequence (Table II). Further studies using better imaging
approaches such as confocal or two-photon microscopy are required to co-localize RKIP with
proteins of known location and function.
RKIP has been previously described as a negative regulator of MAPK activation through the
interaction with Raf-1, MEK, and ERK. This pathway is critical for generating pro-inflammatory
cytokines through the induction of Elk-1 and the transcription of Fos which, when combined
with the protein Jun, form the transcription factor AP-1 (211). By measuring phosphorylatedERK (active) in our studies, we were able to demonstrate that RKIP and p-ERK are indeed
inversely proportional to one another, giving weight to these prior studies (Fig. 4-1C/D).
Surprisingly, even though pERK levels increase as RKIP decreases, a genetic deletion of RKIP
or exogenous blockade did not translate into increased cytokine levels (Fig. 4-6). RKIP has
previously been shown to modulate its substrate affinity after phosphorylation by PKC from Raf1 to GRK2, thus allowing for the transduction of both the Raf-MEK-ERK axis and G-protein
coupled receptors through disinhibition (212). Given this, it is possible that after TLR
stimulation, RKIP also switches affinity away from Raf-MEK-ERK and to another
(MyD88/TRIF) pathway allowing both to proceed simultaneously and cooperatively with
subsequent cytokine production. However, if RKIP is lost completely or is prevented from
functioning properly, this could result in an effect that only allows one of two pathways (ERK)
to transduce a signal without the cooperation of the other. This could effectively override the
high levels of p-ERK and lead to poor cytokine responses. In other words, it may “take two to
tango” in regards to cytokine production, with the possibility that RKIP is utilized to assist in
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pathway cooperativity. A bioinformatic analysis of putative post-translational modification sites
revealed that RKIP has 2 glycosylation sites and at least 32 phosphorylation sites, 13 of which
have higher predictability scores than the validated PKC Ser153 phosphorylation site (Table II).
This suggests that there are numerous possibilities in terms of altered RKIP substrate affinity that
have yet to be described. Another alternative explanation for the p-ERK-cytokine disconnect
would be that exceedingly high levels of p-ERK transmits a negative, instead of a positive, signal
to the cell through a negative feedback loop. This hypothesis is less likely because it would
require the strength of this suppressive signal mediated by p-ERK to shut down normal proinflammatory cytokine production through MyD88 and TRIF signaling which prototypically
does not involve the Raf-MEK-ERK axis, but rather the JNK and p38 MAPKs.
TLRs have been implicated in the pathogenesis of several human inflammatory diseases
including: SIRS/sepsis (213), atherosclerosis (214), inflammatory bowel disease (215),
rheumatoid arthritis (216), asthma (217), systemic lupus erythematosus (36), and
ischemia/reperfusion injury (218). To this end, therapeutic agents have been developed to
decrease the inflammation seen after TLR stimulation by exogenous or endogenous ligands, and
several have been examined in human clinical trials. These include the TLR4-TIRAP small
molecule inhibitor TAK-242 (resartorvid) for sepsis and SIRS (219, 220) and chaperonin-10
(Cpn-10) for RA (221) and SLE (currently recruiting). Many other pharmaceutical companies,
such as Coley, Dynavax, and VentiRx, currently have TLR antagonists in their respective preclinical study pipelines as well (222). RKIP may represent a potential novel therapeutic target
option for these diseases, given that its targeted inhibition using an already commercially
available small molecule inhibitor leads to decreased cytokine responses are TLR stimulation.
However, a more thorough understanding of RKIP’s exact molecular mechanism for facilitating
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PRR responses is needed in order to provide the amount of evidence necessary to proceed into
human disease trials.
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Figure 4-1: Stimulation of wild type splenocytes with LPS leads to a time and dose
dependent disappearance of RKIP protein. (A) Representative immunoblots of bulk
splenocyte lysates from wild type C57BL/6J mice kept either on ice in balanced salt solution
(BSS) or cultured in BSS at 37°C & 5% CO2 for 10 min. or 60 min. (data not shown) in the
presence or absence of 10μg/ml LPS, 50μM of the RKIP inhibitor locostatin, or both. Dimethyl
sulfoxide (DMSO) at the same percent (v/v) as locostatin (~0.1%) was utilized as a vehicle
control. (B) Densitometric quantification of RKIP expression from 4 independent experiments
conducted similarly to Figure 4-1A. RKIP expression was normalized to the loading control
(Actin) to generate an RKIP/Actin ratio, and then the relative quantity of RKIP protein was
determined by setting the ratio of each medium control to 100. Error bars represent SEM and P
values determined by unpaired t test between groups *P<0.05. (C) Immunoblots for RKIP and
phosphorylated ERK-1/2 from lysates of wild type bulk splenocytes that were cultured as in
Figure 4-1A for 10 min. in the presence of various quantities of LPS (range: 1.56-50μg/ml) or
medium alone. (D) Densitometric quantification of RKIP and p-ERK expression from
immunoblot in Figure 4-1C. Data are represented as relative abundance between pERK and
RKIP protein levels.

90

91

Figure 4-2: The inability to detect RKIP protein after PAMP stimulation is generalizable to
multiple TLR ligands. (A) Representative immunoblots of RKIP and Actin protein from lysates
of wild type splenocytes stimulated for 10 min. or 90 min. with titrations of the following TLR
ligands: TLR9- CpG type A (0.33-27μg/ml), TLR9- CpG type B (0.33-27μg/ml), TLR3- Poly
I:C (0.33-81μg/ml), TLR4- LPS (0.33-81μg/ml), and TLR1/2- Pam3CSK4 (0.33-81μg/ml).
Medium controls (M) were utilized for Poly I:C, LPS, and Pam3CSK4 stimulations, and ODNs
containing GpC dinucleotides (**) were used as negative controls for CpG-A, and CpG-B
stimulations. (B) Densitometric quantification of RKIP protein levels from 10 min. (closed
circles) and 90 min. (open circles) stimulations in Figure 4-2A. Data are presented as relative
RKIP expression normalized to actin as described in Figure 4-1B.
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Figure 4-3: Proteosomal degradation and de novo translation impart only minor
contributions to the disappearance of RKIP. (A) Representative immunoblots of wild type
bulk splenocytes stimulated with LPS (50μg/ml) or medium alone for 10 min. or 90 min. in the
presence of the transcriptional inhibitor actinomycin D (100ng/ml) or the translational inhibitor
cyclohexamide (10μg/ml). (B) Immunoblot of bulk wild type splenocytes treated similarly to
Figure 4-3A in the presence or absence of the proteosomal inhibitor lactacystin (2μM). (C)
Densitometric quantification of RKIP protein levels from experiments outlined in Figures 43A/B. Data are presented as relative RKIP expression normalized to actin as described in Figure
4-1B.
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Figure 4-4: The disappearance of RKIP protein after PAMP stimulation may be due to
insoluble complex formation or altered subcellular localization. (A) Immunofluorescent
images of RKIP (green) from wild type bulk splenocytes cultured with either medium or LPS
(50μg/ml) for 10 min. Data are from 2 independent experiments. (B) Wild Type bulk splenocytes
were stimulated for 10 min. or 90 min. in the presence or absence of LPS (25μg/ml). Lysates
from these cultures were generated using the NE-PER subcellular fractionation kit (Thermo
Pierce) which separates cellular protein content into “cytoplasmic” and “nuclear” fractions.
These lysates were immunoblotted for RKIP protein or Hsp90 as a cytoplasmic protein control.
Data are representative images of 5 independent experiments.
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Figure 4-5: Loss of RKIP by genetic knockout or exogenous blockade leads to altered
cytokine and chemokine responses after TLR stimulation. (A) Multiplex cytokine analysis of
bulk mesenteric lymph node (MLN) cells from RKIP-/- or wild type littermate mice stimulated
with CpG-A (9μg/ml) overnight in vitro. Data are represented as relative abundance with the
value of each analyte in wild type littermate stimulations being normalized to 100. (B) ELISA
for IL-6 and TNFα protein in culture supernatants from wild type bulk splenocytes treated
overnight with medium, LPS (50μg/ml), or CpG-A (9μg/ml) in the presence of vehicle (DMSO)
or locostatin (50μM). Error bars represent SEM and P values determined by unpaired t test
between groups using Welch’s correction for variable standard deviations *P<0.05, **P<0.01.
Data are from 2 independent experiments; N=4/group total.
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TABLE II: Bioinformatic Analysis of RKIP in Mus musculus
Prediction

Sequence (Site)

Score

Algorithm

Reference

PBP Family Sig.

YTLVLTDPSRKDPKF
REWHH (64)

N.A.

Predict Protein

Rost et. al. Nucleic
Acids Research.
W321-326 (2004)

Cytoplasmic

N.A.

LOCkey

RGKFKVETFRKK

N.A.

PredictNLS

Localization
Nuclear
Localization
Sequence
Peptidase
Cleavage

No Caspase (1-10),
Factor Xa, Thrombin, or
GzB sites found

N.A.

ExPASy-Peptide Cutter

Asn (N)Glycosylation

NKSG (140)

0.6721
(>0.5 confidence
threshold)

NetNGlyc v1.0

O-Glycosylation

None

N.A.

NetOGlyc v3.1

PKCα/β/γ
Phosphorylation

RGKVETFRKKYNL*
(153)

PKCζ
Phosphorylation

RGKVETFRKKYNL*
(153)

PIP3-binding
domain (PH)

GKFKVETFRKKYNL
(154)

0.114%
(<0.2% high
confidence)
0.003%
(<0.2% high
confidence)
0.112%
(<0.2% high
confidence)
0.849
0.995
0.984
0.998
0.891
0.780
0.958
0.734
0.813
(>0.5 confidence
threshold)
0.846
0.702
0.724
0.515
(>0.5 confidence
threshold)
0.624
0.979
(>0.5 confidence
threshold)

Serine
Phosphorylation**

Threonine
Phosphorylation†

Tyrosine
Phosphorylation‡

MNRPSSISW (51)
NRPSSISWD (52)
PSSISWDGL (54)
PDAPSRKDP (75)
SGPPSGTGL (113)
EQPLSCDEP (132)
EPILSNKSG (139)
LSNKSGDNR (142)
YEQLSGK (185)

YAGVTVDEL (33)
GKVLTPTQV (42)
FKVETFRKK (153)*
PVAGTCYQA (167)

VLSDYVGSG (106)
EWDDYVPKL (176)

Nair. et al. EMBO
Reports. 1(5): 411415 (2000)
Gasteiger et. al. The
Proteomics
Protocols Handbook,
Humana Press.
(2005)
Gupta et. al. Pacific
Symposium on
Biocomputing
7:310-322 (2002)
Steentoft et. al.
EMBO 32(10):147888 (2013).

Scansite v2.0
Motif Scan

John et. al. Nucleic
Acid Res.
31(13):3656-3641
(2003).

NetPhos v2.0

Blom et. al. J. Mol.
Biol. 294(5):13511362 (1999)

* Thr (Ser) 153 phosphorylation site validated in: Lorenz et. al. Nature 426, 574-579 (2003).
** 14 Predicted p-Ser sites; (9/14 have higher predictability than Thr/Ser153)
† 9 Predicted p-Thr sites; (2/9 have higher predictability than Thr/Ser153)
‡ 9 Predicted p-Tyr sites; (2/9 have higher predictability than Thr/Ser153)
N.A. = not acquired
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CHAPTER 5

RKIP IS NECESSARY FOR THE GENERATION OF OPTIMAL TYPE I INTERFERON
RESPONSES DURING B CELL ACTIVATION BY TLR LIGANDS
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ABSTRACT
The activation of APCs by TLR ligands is critical for the host’s initial response to pathogenic
invasion, and the robust inflammatory response generated by these interactions has been
harnessed as a means to enhance the adjuvanticity and effectiveness of vaccine-based therapies.
However, if these responses are directed against endogenous ligands, such as host nucleic acid,
autoimmunity can result, leading to significant morbidity in patients. B lymphocytes play an
underappreciated role in facilitating both advantageous adjuvant responses and deleterious
autoimmunity through the production of protective or destructive antibodies. Interventions that
can affect the response of B cells to TLR ligands could provide a useful therapeutic tool for
autoimmune diseases, or provide valuable insight into B cell adjuvant reactions. Previous data
from our laboratory suggest that RKIP may play an important role in the generation of cytokines
after TLR ligation in splenocytes; nevertheless, RKIP’s functional impact on B cell responses to
PAMPs has not been studied. Here we demonstrate that loss of RKIP results in an attenuated
TRIF-type I IFN transcriptome signature in steady state B cells. This leads to a deficiency in the
generation of IFNα and the interferon-stimulated chemokine CXCL10 in response to TLR3
stimulation with Poly I:C, despite the normalization of many transcripts after TLR-triggering.
Additionally, by blocking RKIP with the small molecule inhibitor locostatin, type-I interferon
responses could also be significantly diminished in wild type B cells, providing evidence that
RKIP may prove to be a valuable therapeutic target for inflammatory diseases potentiated by B
cells and type-I IFNs.
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INTRODUCTION
The largest constituency capable of acting as APCs within the spleen are B lymphocytes. B cells
are responsible for the production of antibodies that help to protect the host eliminate invading
pathogens, but if directed against inappropriate self or innocuous targets, these autoantibodies
can initiate both systemic and localized inflammatory reactions through antibody-dependent
cellular cytotoxicity or immune complex deposition (223). B cell antibody production is also
critical for prophylactic vaccination against many viral and bacterial pathogens (224), and more
recently even parasitic infections and certain cancers (225, 226). Besides the generation of both
protective and destructive adaptive antibody responses, B cells are also important in pathogen
recognition through innate PRRs, antigen presentation and activation of cognate T cells, and
even the production of many pro-inflammatory cytokines and chemokines (IL-6, TNF, Type I
IFNs, CCL2,3,4,5, CXCL10, etc.) that bolster immune responses (227). Thus B cells intersect
adaptive and innate immune pathways.
Because of the pleiotropic effects that B lymphocytes exert on the overall immune response,
having the ability to therapeutically target RKIP in B cells and decrease cytokine production
during auto-inflammatory diseases may provide a useful alternative to direct B cell ablation with
traditional anti-CD20 therapies like rituximab (228). This therapeutic approach can lead to
significantly adverse events including tumor lysis syndrome, cardiac arrest, renal failure, and
progressive multifocal leukoencephalopathy (229). Previous data from our laboratory
demonstrate that RKIP may play an important role in the generation of cytokines during serial
TCR engagement in T cells and after TLR ligation in splenocytes; however, RKIP’s functional
impact on B cell responses, and specifically to PAMPs, is currently unknown.
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It is shown that RKIP is utilized downstream of TLR signaling in B cells, and that it is necessary
for the maintenance of TRIF-Type-I IFN transcriptomic gene signature. Specifically, through
genetic disruption of the RKIP gene in B cells, and through its exogenous inhibition using the
small molecule inhibitor locostatin, we demonstrate that the proper function of RKIP is
necessary for optimal production of IFNα and the interferon stimulated chemokine CXCL10
after exposure to the nucleic acid adjuvant Poly I:C. Due to the critical nature of Type-I IFN
responses in anti-viral immunity, augmentation of Th1 and CTL reactions, contextual immune
suppression, and enhancement of B cell function after PAMP sensing, the ability to
therapeutically inhibit these responses affords a unique opportunity to help control inappropriate
immune reactions that lead to human disease. Finally, these studies provide new insight into the
basic mechanisms of nucleic acid adjuvant usage by B cells, and how RKIP may be important
for the maintenance of these responses during vaccination.
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RESULTS
Since RKIP was involved in the TLR4 response (chapter 4), we hypothesized that after TLR
ligation, RKIP is transiently recruited to a membrane-associated signaling complex. The
functional significance of this interaction was decreased cytokine output after loss of RKIP
through genetic interruption or by therapeutic blockade. In light of these findings, we next sought
to determine the specific nature of the lesion that exists in the absence of RKIP in the context of
TLR ligation. Clinically, this is a very important question given RKIP’s impact on cytokine
production during PRR ligation because it could potentially open the door to both a novel
therapeutic strategy for inflammatory diseases and could shed light on the importance of RKIP
during vaccine-adjuvant based interventions.
Loss of B cells abrogates the disappearance of RKIP after LPS stimulation
In order to choose a model to best study the effects of RKIP loss during TLR responses, we
established four major criteria: 1) select a cell population that played an important and
established role in human inflammatory diseases, 2) test cells that were important for vaccineadjuvant based therapies, 3) study a population that feasibly allowed testing of enough cells to
undertake a systems approach to examine the role of RKIP, and 4) the cells chosen must also
exhibit the same phenomenon of RKIP disappearance after TLR ligation seen in the chapter 4
data set. B lymphocytes were best suited to satisfy these criteria because they are known to be
critical players in many auto-inflammatory conditions such as RA and SLE, they are critical for
the production of protective antibodies during vaccine-based therapies by responding to
adjuvants like monophosphoryl lipid A (MPL), and they make up 40-50% of the splenocytes cell
mass thus providing a feasible number of cells for various experimental techniques (230-235).
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Finally, we stimulated bulk splenocytes from wild type, TCR-βδ-/- (no T cells), and RAG-1-/mice (no B or T cells) and found that the RKIP disappearance after TLR4 ligation with LPS was
greatly diminished when B cells were absent (RAG-/-) but was retained when only T cells were
depleted (βδ-/-), suggesting that B cells were a major contributor to the phenomena outlined in
chapter 4 (Figure 5-1A; compare 0 to 50μg LPS).
RKIP-/- B cells have higher basal levels of phosphorylated-ERK and TLR4/TLR9
engagement leads to transient disappearance of RKIP protein and reciprocal increases in
p-ERK in B cell enriched populations
In order to test the role that RKIP plays in TLR responses in B cells, we began by purifying
naïve “untouched” steady state splenic B cells by magnetic bead negative selection against CD4,
CD43, and Ter119 (B cell isolation kit, Miltenyi Biotec). This method results in a highly
enriched B cell population (~95 ± 2% by CD19 and CD45R expression) that is largely devoid of
NK cells (data not shown), CD8 and CD4 T cells, CD11b+ monocytes (Figure 5-1B). After
purification, approximately 1-2% of the remaining cells are CD11c+, so we cannot rule out the
possibility that some plasmacytoid and other dendritic cell populations may still be contributing
to any effect seen, but they are massively outnumbered by B cells. Using this B cell enriched
population we determined whether p-ERK aberrations existed when RKIP was knocked out. We
examined B cells directly ex vivo from wild type or RKIP-/- mice and found that there were
higher amounts of basal p-ERK levels in B cells devoid of RKIP by immunoblot (Figure 5-2A).
Next, we wanted to determine if this B cell enriched population behaved similarly to bulk
splenocytes in response to TLR ligation. To test this, we treated wild type B cells with 9μg/ml
CpG-B, 50μg/ml LPS, or vehicle alone and harvested cells 10 min, 1 h, 2 h, 4 h, or overnight
after stimulation. We observed that B cells, after stimulation with CpG-B, a TLR ligand with a
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penchant for B cells, begin to have significant amounts of p-ERK after about 1 h and these levels
increase to a maximum at 4 h post stimulation (Figure 5-2B). This maximum p-ERK is preceded
by a moderate decrease in RKIP at 2 h post stimulation, which is consistent with the data in
Figure 4-2A/B. After TLR4 ligation with LPS, however, p-ERK is maximally induced at 1 h
after stimulation and decreased thereafter. Consistent with our findings in bulk splenocytes
presented in chapter 4, this high p-ERK is preceded by a transient disappearance of RKIP 10 min
after TLR4 ligation (Figure 5-2C). Taken together, these data show these splenic B cell enriched
populations perform similarly to bulk splenocytes in the context of RKIP’s behavior after TLR
ligation.
LPS and CpG-B drive divergent B cell cytokine programs partially controlled by RKIP
Next, we wanted to test whether RKIP was necessary for cytokine production in response to LPS
and CpG-B in our enriched B cell population. Therefore, we treated wild type and RKIP-/- B cells
with medium (data not shown), LPS, or CpG-B overnight, and subjected the supernatants from
these cultures to multiplex cytokine array analysis. The vast majority of cytokines were made
similarly between wild type and RKIP-/- (Figure 5-3A), and some were not produced in response
to either CpG-B or LPS including: IL-3, IL-4, IL-5, IL-7, IL-12, IL-13, IL-17, IFNγ, M-CSF,
Eotaxin, CXCL5, and LIF (data not shown). Of the cytokines that were different, most were
decreased in RKIP-/- B cells compared to wild type, except for CCL5 in response to CpG-B, and
IL-2 in response to LPS (Figure 5-3B). Also, we observed that the cytokine programs that were
generated in response to LPS and CpG-B varied from one another. For example, CpG-B, which
has previously been described as a strong stimulator of B cell responses (236), was much more
potent at inducing pro-inflammatory cytokines such as: IL-1α/β, IL-6, TNFα, GM-CSF, and IL9. Also, CpG-B induced high quantities of CCL2, CCL3, and CCL4 chemokines compared to
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LPS (Figure 5-3C). In contrast, LPS was able to potently stimulate CXCL10 and CCL5
chemokines more than CpG-B, which implies that these chemokines are more likely to be
associated with TRIF stimulation rather than MyD88. Given the vastly different cytokine profiles
in response to stimulation through MyD88 alone or in conjunction with TRIF, we next tried to
validate these findings by conventional ELISA by testing Poly I:C in order to examine TRIF
stimulation. We stimulated our naïve splenic B cell enriched populations with medium, LPS,
Poly I:C, or CpG-B overnight and measured IL-1β, CCL2, CCL3, CCL5, and CXCL10 in the
culture supernatants. We also measured the type I interferons IFNα, and IFNβ, given that our
multiplex array suggested a potential effect in the TRIF pathway. We found that several
cytokines were lower than the lowest limit of detection by conventional ELISA after TLR
ligation including IL-1β, CCL2, and IFNβ (data not shown). CCL3, which had no genotype
effect in our multiplex array, also showed no difference by ELISA (Figure 5-3D). When testing
for CCL5, CXCL10, and IFNα, we found that RKIP-/- B cells made less of these cytokines
compared to wild type (Figure 5-3D & Figure 5-8B), but only when the TRIF signaling pathway
was driven alone with Poly I:C. Taken together, these data suggest that RKIP may be necessary
for TRIF-dependent cytokine production.
Naïve RKIP-/- B cells have an attenuate transcriptome which normalizes rapidly after TLR
ligation with LPS or CpG-B
In order to better understand the altered cytokine responses in B cells devoid of RKIP, we
isolated total mRNA from wild type and RKIP-/- B cells that were naïve or stimulated for 1 h in
vitro with either LPS or CpG-B for RNA sequencing. Interestingly we found that in naïve B
cells, 884 genes (3.7% of total) were significantly different in RKIP-/- compared to wild type
(Figure 5-4C). Of these 884 genes that were significantly different, 870 were reduced in the
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RKIP-/- B cells compared to wild type, suggesting that in the absence of RKIP, these cells have a
transcriptome that is attenuated at baseline (Figure 5-4A). However, when RKIP-/- B cells were
stimulated with either LPS or CpG for just 1 h, their transcriptomes became largely normalized
compared to wild type (Figure 5-4B). LPS seems to have a slightly stronger effect on
transcriptome normalization compared to CpG-B, most likely because of its ability to trigger
both the MyD88 and TRIF pathways simultaneously. In fact, after stimulation, the majority of
significantly altered genes in RKIP-/- B cells were increased rather than decreased, suggesting
that even though RKIP-/- B cells may start at a disadvantage at the mRNA level, the
transcriptome can be rapidly normalized, or even exhibit slightly higher induction of some genes
after TLR ligation (Figure 5-4C).
Pathway analysis of altered genes in RKIP-/- B cells reveals an enrichment of pathways
involved in mitochondrial function, TLR signaling, and cytokine responses
Next, we wanted to determine whether the genes that were significantly different in untouched
RKIP-/- B cells were restricted to specific pathway alterations, or if the transcriptome attenuation
was a global effect on all pathways. In order to test this, we subjected all of the genes that were
statistically significantly different between wild type and RKIP-/- and had a log2 (fold change)
greater than ± 1.2 (absolute fold change greater than ± 2.3) to pathway analysis using the
Ingenuity Pathway Analysis (IPA) software algorithm. IPA identified 371 pathways that
contained at least one of our genes of interest, of those 371, 98 had enrichment not due to chance
(Table III). The most significantly enriched pathways in RKIP-/- B cells were those that were
important for mitochondrial function, TLR signaling, and cytokine responses (Figure 5-5A).
Additionally, pathways important for proliferation, apoptosis, and co-stimulation were also
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enriched, but to a lesser degree. Most of these canonical pathways share important genes
between them, which could explain why they showed similar enrichment.
RKIP-/- B cells do not have significantly altered basal or maximal mitochondrial respiration
before or after stimulation with TLR ligands
Our IPA analysis determined that the most significantly enriched pathway in RKIP-/- B cells was
composed of 22 different genes important for mitochondrial function. These genes were
comprised of components of each of the major complexes involved in the electron transport
chain, as well as, several associated kinases known to modulate their function (Table IV).
Because all of the identified genes were decreased in B cells devoid of RKIP, we hypothesized
that oxidative phosphorylation may also be diminished, and may be a contributing factor to
decreased cytokine output. Also, given recent evidence that metabolic products can posttranscriptionally regulate cytokine translation (237), we thought it necessary to test the
mitochondrial function of RKIP-/- B cells. In order to determine if loss of RKIP played a role in
oxidative phosphorylation, we stimulated B cells from wild type (C57BL/6J), RKIP-/-, RKIP+/-,
and RKIP+/+ mice with LPS, CpG-B, Poly I:C, PMA + ionomycin, or medium alone for 1 h, and
then analyzed their rate of oxygen consumption (OCR) on the Seahorse XF96 extracellular flux
analyzer which measures several parameters of mitochondrial function (Figure 5-6A). We
observed no significant differences in either the basal OCR (Figure 5-6B) or maximum OCR
(Figure 5-6C) between groups regardless of stimulation. Thus, 1 h after TLR stimulation no
difference was seen but it is possible that during the stimulation metabolic differences occurred,
but this was not tested. It remains open that early during stimulation, metabolic changes may
occur, but if so, this did not last past 1 h.
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Steady state RKIP-/- B cells have an attenuated TRIF-Type I Interferon transcriptome
signature
After demonstrating that mitochondrial function was relatively normal in RKIP-/- B cells, we
next re-examined the RNA sequencing data and IPA pathway analysis to assess the TLR
signaling pathways. We observed by RNAseq that untouched naïve RKIP-/- B cells exhibited a
decreased TRIF-type I interferon gene signature that included significant reductions in upstream
mediators of type I interferon generation including: Ticam1 (TRIF), Traf3, Irf3, Irf5, Irf7, Ikbke
(IKKε), as well as a subunit of the type I interferon receptor (Ifnar1). Other pathway members
including: Tmem173 (STING), Tram, Tank, Tbk1, and Mavs (IPS-1) were also reduced, but not
significantly so (Figure 5-7A, left panel). Naïve B cells devoid of RKIP also had significant
reductions in Tlr3 and Tlr9 transcript levels, but the rest of their PRRs were, for the most part,
intact (Figure 5-7A, right panel). Additionally, the MyD88 and NF-κB signaling pathways were
also somewhat decreased, but this was less robust compared to the TRIF-type I interferon
pathway (Table V). Importantly, after stimulation with either LPS or CpG-B for 1 h, we
discovered that the vast majority of gene transcripts that were affected at baseline had
normalized to wild type levels, with the exception of Irf7 after CpG-B stimulation (Table VI). To
avoid the complication of using disadvantaged RKIP-/- B cells, we employed locostatin to test
RKIP inhibition in wild type cells. We found that after 2 h of Poly I:C stimulation in wild type B
cells, in the presence of absence of the RKIP inhibitor locostatin, there was no significant
difference in the transcript levels of Irf3, Irf5, Irf7, Traf3, Tbk1, Ikbke, or Ifnar1 between B cells
with RKIP inhibition or none (Figure 5-7B). Nevertheless, RKIP inhibition had an effect on Ifna
transcription when wild type B cells were pretreated with locostatin prior to Poly I:C stimulation.
The amount of Ifna mRNA was significantly reduced 1-2 h after stimulation compared to vehicle
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pre-treated B cells (Figure 5-7C). However, after approximately 6 h post stimulation, the
transcript levels of Ifna were indistinguishable between groups. Taken together these data
suggest that RKIP may be important for the early induction of Ifna, but there are mechanisms in
place that allow the transcript levels of this gene to approximate normal with a sustained
stimulus.
RKIP optimizes IFNα synthesis and the Type I IFN stimulated chemokine CXCL10
following TLR3 ligation
In order to determine whether the perturbations in TRIF-type I interferon seen in RKIP-/- B cells,
or RKIP blockade, had any functional consequences, we tested cytokine output from these
pathways. First, enriched B cells populations from wild type and RKIP-/- mice were stimulated
with Poly I:C with or without RKIP blockade for 6 h (data not shown) or overnight and CXCL10
and CCL5 were measured in the culture supernatants. Consistent with findings in Figure 5-7, we
found a severely diminished (~30% of wild type) amount of the interferon-stimulated chemokine
CXCL10 in RKIP-/- B cells after stimulation (Figure 5-8A). In contrast, CCL5, a chemokine only
partially dependent upon TRIF signaling, was slightly decreased (~70% of wild type).
Importantly, RKIP blockade in wild type B cells mirrored CXCL10 output from RKIP-/- B cells.
Nevertheless, locostatin had little to no effect on RKIP-/- B cells, suggesting a moderate degree of
specificity (Figure 5-8A).
To test the therapeutic relevance of these findings, we repeated the experiment described in
Figure 5-8A in wild type B cells alone in the context of type I interferon receptor blockade (antiIFNAR1) or isotype control. First, RKIP blockade potently inhibited IFNα production at 6 h in
culture and during its feed-forward enhancement after overnight (Figure 5-8B). In fact, the
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reduction IFNα was even greater after overnight culture, suggesting the RKIP may play a role in
both the initial production of type I interferons, but also in their ability to enhance their own
production through a feed-forward loop. Consistent with our findings in Figure 5-8A, we also
found a significant decrease in CXCL10 production from wild type B cells after RKIP inhibition,
and to a lesser degree CCL5 (Figure 5-8B). Importantly, in the presence of type-I interferon
receptor blockade CXCL10 production was abolished, demonstrating its dependence on type-I
interferon signaling. In contrast, CCL5 production was independent of IFNAR blockade. Taken
together, these data suggest that RKIP may be a valuable therapeutic target to inhibit the
production of type I interferons and their associated downstream effectors during TLR responses
in APCs.

113

DISCUSSION
B cells are well known to impact vaccine development due to their antibody producing capacity,
they are nevertheless understudied cytokine producing cells that may contribute to vaccine
adjuvanticity and the potentiation of autoimmune diseases (238-241). One way B cells can
contribute to adjuvant responses is by producing cytokines in response to PAMPs (121, 238, 242,
243). Through these interactions, B cells can be significant producers of both cytokines and
chemokines which contribute to the establishment of the inflammatory milieu and chemotactic
locomotor gradients (244, 245). Recently, there have been renewed efforts to better utilize B cell
responses to nucleic acid adjuvants to foster vaccine development for HIV, malaria, intracellular
pathogens, and other emerging infections (238, 246, 247). A successful application of this
strategy has been the mechanistic reexamination of the YF-17D vaccine against yellow fever
causing Flaviviridae which provides protection through TLR7 ligation and Type-I IFN
production (248-250). Analogously, B cell depleting agents such as Rituximab (anti-CD20
mAb) have been utilized as a successful treatment modality for autoimmune diseases such as
rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and many others (233,
251). What both of these reactions have in common is the necessity of B cells to respond to
initial triggering through their PRRs in order to produce productive reactions in vitro and in vivo
(252).
Previous data from our laboratory implicated RKIP as an important molecule for productive
cytokine responses after TLR signaling in splenocytes, yet the role that RKIP plays in these
critical initiating events of PRR ligation in B cells is unknown and provides a fertile area of
study. We initially observed that depleting B cells from our bulk splenocyte populations using
RAG-/- mice abrogated our central finding in chapter 4 (i.e. the “disappearance” of RKIP shortly
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after TLR ligation), while losing only T cells (βδ-/- mice) kept this phenomenon intact (Fig. 51A). The fact that B cells exhibited similar responses to bulk splenocytes, in terms of RKIP after
LPS and CpG stimulation and high basal p-ERK levels when lacking RKIP, verified that this cell
population was at least a significant contributor to our findings in chapter 4 (Fig. 5-2A-C).
However, because our method to enrich naïve splenic B cell populations does not robustly
deplete CD11c+ cells (Fig. 5-1B), it prevents us from ruling out the possibility that conventional
and plasmacytoid dendritic cells might also play a role in our studies. Although the likelihood of
pDC effects may be marginal given that they do not express TLR3 (253) and that TLR9 ligation
leads to IFNα production through IKKα and IRF7 (42), which was not seen in our studies (Fig.
5-3D).
Upon investigation of the cytokine milieu driven by either LPS or CpG-B in B cells, we
observed vastly divergent outputs depending on the nature of the ligand. CpG-B was much more
potent than LPS in inducing pro-inflammatory cytokine production including IL-1, IL-6, TNF,
GM-CSF, and others. However, LPS stimulated B cells were more efficiently able to produce
factors normally associated with TRIF, namely CXCL10 and CCL5 (Fig. 5-3C). Interestingly,
RKIP seemed to be more important for the cytokine output in response to CpG-B, rather than
LPS, in B cells (Fig. 5-3B). This could be due to several factors including the ability of LPS to
signal through both MyD88 and TRIF, potentially giving this stimulus a way to circumvent small
signaling lesions due to heterologous pathway activation. Consistent with this hypothesis, when
inducing the TRIF pathway alone with the dsRNA Poly I:C, we observed attenuated production
of several TRIF-associated cytokines including IFNα, CXCL10, and CCL5, but not CCL3 which
is made indiscriminately in response to NF-κB activation (Fig 5-3D). Nevertheless, consistent
with Figure 4-5A, RKIP-/- cells were altered in their output of some cytokines but not others.
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Because the generation of many cytokines is dependent on the cooperative nature of several
pathways, it becomes very difficult to pinpoint the exact location of RKIP function.
In order to better understand the molecular mechanisms of these differential adjuvant responses,
as well as to garner new insights into how RKIP affects cytokine production from B cells, we
utilized total transcriptome RNA sequencing of naïve, LPS, and CpG-B stimulated B cells from
wild type and RKIP-/- mice. This approach has, to our knowledge, not been previously utilized to
interrogate the RKIP pathway during TLR signaling. Through RNAseq, we discovered that the
vast majority (~96.2%) of mRNAs were unaffected in RKIP-/- B cells. However, there were 884
mRNAs that had significantly different expression levels in naïve RKIP-/- B cells compared to
wild type, and interestingly, of these mRNAs, 870 (98.4%) were decreased in RKIP deficient
cells (Fig. 5-4A). Importantly, we also observed that within 1 hour of TLR ligation with either
LPS or CpG-B many of these transcripts normalize to wild type levels, or in some cases, are
induced even higher than wild type (Fig. 5-4B/C). This suggests that RKIP-/- B cells, may start
off at a signaling disadvantage due to their partially attenuated transcriptome, but may catch up,
at least at the level of transcription, over time. This is an excellent example of why it is difficult
to compare a knockout mouse to wild type due to a disadvantage in the steady state, even though
there is no obvious phenotypic defect.
In order to determine if the affected transcripts from our RNA sequencing analysis were
evidence of specific pathway alterations or stochastic changes within the transcriptome, we used
Ingenuity’s pathway analysis (IPA) in conjunction with the Database for Annotation,
Visualization and Integrated Discovery (DAVID) to mine for enrichment of particular pathways
based on our list of altered genes. We discovered that although many canonical signaling
pathways were affected, there was a significant enrichment in pathways involved in
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mitochondrial function, TLR signaling, cytokine responses, co-stimulation, and survival (Fig. 55A, Table III).
Recent findings from Dr. Pearce’s laboratory and others have implicated products involved in
cellular metabolism as regulators of cytokine production post-transcriptionally (237), as well as,
from an energetics standpoint (254). Because genes involved in mitochondrial function were the
most highly enriched pathway within RKIP-/- B cells, we tested the capacity of these cells to
properly undergo oxidative phosphorylation ex vivo and after stimulation with TLR ligands.
Despite the fact that loss of RKIP led to a number of decreased transcripts involved in the
oxidative phosphorylation machinery (Table IV), RKIP-/- B cells had no significant difference in
their oxygen consumption rates, and thus their ability to undergo oxidative phosphorylation,
before or after stimulation with LPS, CpG-B, or Poly I:C compared to wild type (Fig. 5-6A/B).
With mitochondrial dysfunction providing little evidence to explain the aberrations in cytokine
production, we next turned our attention to evaluating mRNAs involved in TLR signaling. Upon
examination, we observed that naïve RKIP-/- B cells had a greatly attenuated “Type-I IFN gene
signature”, previously described by others (255), that included significantly decreased levels of
Ticam1, Traf3, Irf3, Irf5, Irf7, Ifnar1, Ikbke, and others (Fig. 5-7A). RKIP-/- B cells also had
lower expression levels of some genes involved MyD88 and NF-κB signaling as well, but to a
lesser degree (Table V). Interestingly, these cells also had lower basal expression of Cd40, which
could suggest that in addition to having an attenuated TLR signaling apparatus, these B cells may
have trouble accepting help from cognate T helper cells through CD40L-CD40 interaction.
Because it is still unknown exactly how B cells integrate the initial activation events of PRR
ligation with recognition of antigen through the BCR and T cell help via CD40L, it is unclear
exactly how large of a disadvantage diminution of two critical signaling events would place
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RKIP-/- B cells at. Future studies looking at CD40L-mediated help, as well as BCR crosslinking
effects in the context of these attenuated pathways in RKIP-/- mice should be conducted before
conclusions can be made regarding effects on the entirety of the B cell response.
However, as with the broad overview of transcriptomic changes between naïve and TLR
triggered B cells, most of these deficits in transcript levels are normalized after stimulation, with
the exception of Irf7 after TLR9 ligation (Table VI). This normalization was confirmed
independently of RNA seq by qPCR analysis of several genes associated with the Type-I IFN
signature after Poly I:C stimulation with or without RKIP blockade (Fig 5-7B). Nevertheless,
despite the correction of genes involved in the Type-I IFN generating signaling machinery,
transcript levels of Ifna were still decreased until about 6 hours post TLR3 ligation with Poly I:C
in the presence of RKIP blockade in wild type B cells (Fig. 5-7C). The functional effect of this
was a significant reduction in both IFNα protein and the interferon-dependent chemokine
CXCL10 (Fig. 5-8B). The abatement of these two important molecules was also confirmed in
RKIP-/- B cells (Fig. 5-8A, Fig 5-3D). Additionally, we have observed that after adoptive transfer
of wild type TCR transgenic T cells into RKIP deficient hosts, these T cells have a decreased
migratory capacity to peripheral tissues, especially to the liver (data not shown). This migration
into the hepatic circulation has been shown to be dependent on the generation of chemotactic
gradients involving CXCL9 and CXCL10 and their interaction with the CXCR3 receptor on
circulating T cells (256), and thus is consistent with the notion that RKIP-/- mice have deficits in
the production of these cytokines. Finally, CCL5 was also decreased in the presence of RKIP
blockade; however, unlike CXCL10, CCL5 is not dependent on type-I IFN signaling and is only
partially dependent on downstream TRIF signaling (Fig.5-8B). Currently, it is still unclear
whether or not the role that RKIP plays in the generation of IFNα and its sequelae and the
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production of CCL5 are one in the same. Given that the MyD88 and NF-κB signaling pathways
also were affected in RKIP-/- B cells, and that they also contribute to the production of CCL5, it
is conceivable that RKIP’s role in CCL5 generation may be independent of its effects on the
TRIF-Type-I IFN pathway.
Previous work from other laboratories have established that productive B cell responses to
nucleic acid PRR ligands are dependent upon the fidelity of the Type-I IFN positive feed forward
loop (257). This is due in part to the up-regulation of TLR3 and TLR7 expression which provide
more robust reactions to occur following initial activation (258), and the increase production of
B cell survival factors, such as BAFF (259). This feed-forward loop is exemplified by the
increase in IFNα production between 6 hours after Poly I:C stimulation and overnight (Fig. 5-8B,
left panel). Interestingly, RKIP blockade reduced both the initial production of IFNα (6 h) and its
enhanced feed-forward production (O/N), perhaps even to a larger extent. These data suggest
that RKIP may play a role in facilitating the Type-I IFN response both before and after the
generation of IFNα per se. The mechanism by which RKIP mediates these effects requires more
study, however we hypothesize that RKIP may act by stabilizing signaling complexes upstream
of Type-I IFN production (most likely at the level of TRAF3, TBK-1, and IKKε) and/or coupling
the Type-I IFN receptor to its downstream machinery which would facilitate proper feed-forward
signaling. This hypothesis will be expanded upon in chapter 6.
Irrespective of the exact molecular role that RKIP plays in generation of Type-I IFNs, the fact
that its functional blockade is druggable and can essentially attenuate production of IFNα, and its
related effectors, provides a novel target for therapeutic intervention in auto-inflammatory
diseases that are predominated or potentiated by Type-I IFNs, such as SLE.
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Figure 5-1: Loss of B cells abrogates the disappearance of RKIP after LPS stimulation
(A) Representative immunoblot of RKIP in bulk splenocyte lysates from wild type C57BL/6J
mice, T cell deficient TCR-βδ-/- mice, or T and B cell deficient RAG-1-/- mice stimulated for 10
min with either 10μg/ml or 50μg/ml of LPS. Balanced slat solution (BSS) was used as the
vehicle control (0μg/ml LPS). N.A. = not acquired. (B) Representative flow cytometry plots
illustrating the gating strategy for B cell enrichment before and after magnetic bead purification.
Naïve “untouched” B cells were isolated by negative selection after incubation with anti-CD4,
anti-Ter119 (expressed on all leukocytes except B cells) (260), and anti-CD43 (expressed on all
T and B cells that have previously been activated) (261) antibody-magnetic bead complexes. The
average purity of B cell enriched populations is 95 ± 2% (N>50 mice).
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Figure 5-2: RKIP-/- B cells have higher basal levels of phosphorylated-ERK (A)
phosphorylated-ERK/ERK-1 ratios determined by densitometric analysis of lysates from
unstimulated splenic B cell enriched populations. TLR4 and TLR9 ligation leads to transient
disappearance of RKIP protein and reciprocal increases in p-ERK in B cell enriched
populations (B) Immunoblots of RKIP, pERK-1/2, and ERK-1 in splenic B cell enriched
populations from wild type mice stimulated with either media, 50μg/ml LPS, or 9μg/ml CpG-B
for 10 min, 1 h, 2 h, 4 h, or overnight. Data are representative of 3 independent experiments.
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Figure 5-3: LPS and CpG-B drive divergent B cell cytokine programs partially controlled
by RKIP (A-C) Multiplex cytokine array of naïve splenic B cells stimulated with either medium
(data not shown), 50μg/ml LPS, or 9μg/ml CpG-B overnight. Data are presented as RKIP-/quantities or each cytokine normalized to wild type (set to 100). Error bars represent mean ±
SEM, and data are from 3 independent experiments; N=6/group. P values determined using t
tests between 2 groups, using Welch’s correction where necessary; *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001. (D) Naïve splenic B cells stimulated as in Figure 5-3A with the
addition of 50μg/ml Poly I:C overnight. Supernatants from these cultures were used to determine
quantities of CCL5, CXCL10, CCL3, and IFNα by ELISA. Error bars represent mean ± SEM,
and data are from 3 independent experiments; N=6-9/group. P values determined using t tests
between 2 groups, using Welch’s correction where necessary; *p<0.05, **p<0.01.
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Figure 5-4: Naïve RKIP-/- B cells have an attenuated transcriptome which normalizes
rapidly after TLR ligation with LPS or CpG-B (A) Heat map representing the expression of
the top 400 altered genes between wild type and RKIP-/- naïve B cell transcriptomes. Color
intensity represents relative expression of gene transcripts (0 = min, 100 = max). Total mRNA
sent for RNA sequencing was pooled from 3 individual mice in each group. (B) Volcano plots
showing significantly increased and decreased genes from naïve splenic B cell enriched
populations, or after 1 h stimulation with 50μg/ml LPS or 9μg/ml CpG-B. Numbers represent
percentages of all genes analyzed (23,235). (C) Table showing the number of genes that were
statistically significantly up-regulated or down-regulated between naïve, LPS stimulated, or
CPG-B stimulated wild type and RKIP-/- B cells.

126

127

Figure 5-5: Pathway analysis of altered genes in RKIP-/- B cells reveals an enrichment of
pathways involved in mitochondrial function, TLR signaling, and cytokine responses (A)
Top 30 most enriched pathways in naïve RKIP-/- B cells graphically represented as –log10(pvalue). Briefly, genes of interest were identified by taking all genes that were found to be
statistically significantly different between experimental groups and had a relative fold change of
> ±1.2, and subjected to functional pathway analysis using the IPA knowledge database
(Ingenuity Systems; Redwood City, CA, USA). IPA cross-references a user’s list of genes of
interest to known canonical signaling pathways and determines the level of enrichment of a
given pathway using the user’s gene list and fold changes. IPA then calculates a P value based
on this enrichment using Fisher’s exact test.
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Figure 5-6: RKIP-/- B cells do not have significantly altered basal or maximal mitochondrial
respiration before or after stimulation with TLR ligands (A) Technical diagram showing
normal oxygen consumption rate curves and different measurable parameters by Seahorse
extracellular flux analysis. Oligomycin is used to inhibit ATP synthase and inhibit mitochondrial
respiration, FCCP uncouples the electron transport chain (ETC) allowing for maximal respiration
capacity, and antimycin A/rotenone disrupt the ETC preventing oxygen utilization. (B-C)
Splenic B cell enriched populations from C57BL/6J, RKIP-/-, RKIP+/-, and wild type littermates
were cultured for 1 h with medium, 50μg/ml LPS, 50μg/ml Poly I:C, 9μg/ml CpG-B, or PMA +
ionomycin and subsequently mitochondrial function was assessed by measuring oxygen
consumption rates (OCR) expressed as pMoles/min. Basal mitochondrial rates (B) were
determined by averaging OCRs at 0, 6, and 12 min (before oligomycin administration) for each
mouse. Maximal mitochondrial rates (C) were determined by averaging OCRs at 33 and 40 min
(4 min after FCCP administration). N=9 for C57BL6J and RKIP-/- groups from 3 independent
experiments, and N=3 for RKIP+/- and RKIP+/+ groups from 1 experiment.
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Figure 5-7: Steady state RKIP-/- B cells have an attenuated TRIF-Type I Interferon
transcriptome signature (A) Comparison of genes important for TRIF-type I interferon
signaling (left panel) and pattern recognition receptor genes (right panel) in naïve wild type and
RKIP-/- B cells from RNA sequencing data in Figure 5-4. Data are represented as relative
abundance normalized to wild type quantities of each gene (set to 100). P-values calculated by
Otogenetics normalized to FPKM using cufflinks software; *p<0.05, **p<0.01, ***p<0.001. (B)
qPCR analysis of important TRIF-type I interferon genes from wild type and RKIP-/- B cells
stimulated in vitro with 50μg/ml Poly I:C and 5μM locostatin or vehicle control (DMSO at same
(v/v) percent) for 2 h. Data are expressed as fold change (2-∆∆Ct), error bars represent mean ±
SEM, data are from 1 experiment, N=3/group. (C) qPCR analysis of IFNα transcript levels from
wild type B cells stimulated with 50μg/ml Poly I:C and 5μM locostatin or vehicle control
(DMSO at same (v/v) percent) for 1, 2, 4, or 8 h. In 2 of 3 experiments, locostatin was given
concomitantly with Poly I:C, and in 1 of 3 experiments, locostatin was given 10 min prior to
Poly I:C stimulation. Error bars represent mean ± SEM, data are from 3 independent experiments
N=3 (1 h), 9 (2 h, 4 h), or 6 (8 h); **p<0.01.
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Figure 5-8: RKIP optimizes IFNα synthesis and the Type I IFN stimulated chemokine
CXCL10 following TLR3 ligation (A) ELISA for CXCL10 and CCL5 from culture
supernatants of wild type and RKIP-/- B cells stimulated in vitro with 50μg/ml Poly I:C and 5μM
locostatin or vehicle control (DMSO at same (v/v) percent) overnight. Error bars represent mean
± SEM, data are from 1 experiment, N=3/group; **p<0.01, ****p<0.0001. (B) ELISA for
CXCL10, CCL5, and IFNα from culture supernatants treated similarly as described in Figure 58A for 6h or overnight in the presence of anti-IFNAR1 blocking antibody (10μg/well) or isotype
control (10μg/well). Error bars represent mean ± SEM data are from 3 independent experiments,
N=6/group (6 h) and N=9/group (O/N); *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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TABLE III: Ingenuity Analysis of Pathways Enriched in RKIP-/- B Cells
Pathway
Mitochondrial Dysfunction
Induction of Apoptosis by HIV1
CD28 Signaling in T Helper Cells
CD40 Signaling
TNFR1 Signaling
TNFR2 Signaling
iCOS-iCOSL Signaling in T Helper Cells
April Mediated Signaling
B Cell Activating Factor Signaling
TWEAK Signaling
Activation of IRF by Cytosolic Pattern Recognition Receptors
Lymphotoxin β Receptor Signaling
Toll-like Receptor Signaling
PKCθ Signaling in T Lymphocytes
PI3K Signaling in B Lymphocytes
B Cell Receptor Signaling
Dendritic Cell Maturation
Role of NFAT in Regulation of the Immune Response
mTOR Signaling
T Cell Receptor Signaling
RANK Signaling in Osteoclasts
Apoptosis Signaling
4-1BB Signaling in T Lymphocytes
EGF Signaling
Huntington's Disease Signaling
Oxidative Ethanol Degradation III
Tryptophan Degradation X (Mammalian, via Tryptamine)
Gαq Signaling
CD27 Signaling in Lymphocytes
IL-1 Signaling
Type I Diabetes Mellitus Signaling
Ethanol Degradation IV
Ethanol Degradation II
Antigen Presentation Pathway
Ceramide Signaling
CCR5 Signaling in Macrophages
SAPK/JNK Signaling
Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes
Interferon Signaling
IL-10 Signaling
Non-Small Cell Lung Cancer Signaling
Androgen Signaling
NGF Signaling
Regulation of eIF4 and p70S6K Signaling
FcγRIIB Signaling in B Lymphocytes
CREB Signaling in Neurons
EIF2 Signaling
Phenylethylamine Degradation I
α-tocopherol Degradation
Estrogen Receptor Signaling
CTLA4 Signaling in Cytotoxic T Lymphocytes
Role of NFAT in Cardiac Hypertrophy
α-Adrenergic Signaling
Caveolar-mediated Endocytosis Signaling
Small Cell Lung Cancer Signaling
Calcium-induced T Lymphocyte Apoptosis
IL-4 Signaling
Role of RIG1-like Receptors in Antiviral Innate Immunity
14-3-3-mediated Signaling
IL-12 Signaling and Production in Macrophages
Systemic Lupus Erythematosus Signaling
Histamine Degradation
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p-value

-log (p-value)

1.28825E-06
4.36516E-05
5.7544E-05
0.000134896
0.000223872
0.000223872
0.000251189
0.000295121
0.00042658
0.000549541
0.00057544
0.000676083
0.000676083
0.000676083
0.000676083
0.000812831
0.001
0.001230269
0.001380384
0.001584893
0.002041738
0.002041738
0.002238721
0.004073803
0.004466836
0.005370318
0.00676083
0.007079458
0.007943282
0.008128305
0.008128305
0.008317638
0.00851138
0.00851138
0.009120108
0.009120108
0.009332543
0.01
0.01
0.01
0.01
0.01
0.01
0.010715193
0.010964782
0.010964782
0.011481536
0.012022644
0.012022644
0.012589254
0.013489629
0.014125375
0.014454398
0.015488166
0.015488166
0.015848932
0.016595869
0.016982437
0.017782794
0.019054607
0.019498446
0.019952623

5.89
4.36
4.24
3.87
3.65
3.65
3.6
3.53
3.37
3.26
3.24
3.17
3.17
3.17
3.17
3.09
3
2.91
2.86
2.8
2.69
2.69
2.65
2.39
2.35
2.27
2.17
2.15
2.1
2.09
2.09
2.08
2.07
2.07
2.04
2.04
2.03
2.00
2.00
2.00
2.00
2.00
2.00
1.97
1.96
1.96
1.94
1.92
1.92
1.9
1.87
1.85
1.84
1.81
1.81
1.8
1.78
1.77
1.75
1.72
1.71
1.7

TABLE III: Ingenuity Analysis of Pathways Enriched in RKIP-/- B Cells (cont.)
Pathway
Tumoricidal Function of Hepatic Natural Killer Cells
IL-17A Signaling in Gastric Cells
Fc Epsilon RI Signaling
Fatty Acid α-oxidation
Renin-Angiotensin Signaling
PDGF Signaling
Chronic Myeloid Leukemia Signaling
GNRH Signaling
NF-κB Signaling
Granzyme B Signaling
CDP-diacylglycerol Biosynthesis I
NRF2-mediated Oxidative Stress Response
Protein Kinase A Signaling
Role of PI3K/AKT Signaling in the Pathogenesis of Influenza
UVB-Induced MAPK Signaling
Role of PKR in Interferon Induction and Antiviral Response
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis
TREM1 Signaling
Integrin Signaling
Putrescine Degradation III
IL-8 Signaling
Superpathway of Inositol Phosphate Compounds
GDNF Family Ligand-Receptor Interactions
Death Receptor Signaling
Phosphatidylglycerol Biosynthesis II (Non-plastidic)
Noradrenaline and Adrenaline Degradation
Aryl Hydrocarbon Receptor Signaling
Virus Entry via Endocytic Pathways
FAK Signaling
UVA-Induced MAPK Signaling
Glucocorticoid Receptor Signaling
Acetyl-CoA Biosynthesis III (from Citrate)
Gap Junction Signaling
iNOS Signaling
Myc Mediated Apoptosis Signaling
D-myo-inositol (1,4,5)-trisphosphate Degradation
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p-value

-log (p-value)

0.019952623
0.019952623
0.023988329
0.024547089
0.025118864
0.025703958
0.026915348
0.029512092
0.029512092
0.029512092
0.029512092
0.030902954
0.031622777
0.032359366
0.032359366
0.033113112
0.033884416
0.035481339
0.035481339
0.035481339
0.036307805
0.036307805
0.03801894
0.040738028
0.041686938
0.043651583
0.044668359
0.045708819
0.045708819
0.045708819
0.046773514
0.046773514
0.046773514
0.047863009
0.047863009
0.047863009

1.7
1.7
1.62
1.61
1.6
1.59
1.57
1.53
1.53
1.53
1.53
1.51
1.5
1.49
1.49
1.48
1.47
1.45
1.45
1.45
1.44
1.44
1.42
1.39
1.38
1.36
1.35
1.34
1.34
1.34
1.33
1.33
1.33
1.32
1.32
1.32

TABLE IV: Altered Genes Important for Mitochondrial Function in RKIP-/- B Cells
Relative Expression
Gene

Wild Type

RKIP-/-

Map2k4
Ndufv1
Atp5d
Cox6a1
Ndufs7
Cox8a
Ndufa7
Ndufb8
Dhodh
Ndufa1
Ndufa2
Ndufa13
Ndufb10
Fis1
Ndufs8
Txn2
Ndufb7
Cyc1
Cyb5r3
Uqcrc1
Uqcrq
Pink1

6.02709
49.028
79.958
101.328
183.742
89.4472
389.806
333.707
6.02206
207.983
628.054
105.126
360.958
142.321
221.571
113.475
89.5458
15.5698
10.2153
84.7091
185.161
5.79479

2.18678
18.897
32.0431
39.5858
55.3997
25.6215
175.586
120.657
1.70485
65.7994
215.532
36.7641
143.939
60.9672
94.443
39.5416
36.1698
4.84798
2.45583
33.7325
79.4686
1.79302

Function
JNK-K
NADH dehydrogenase (Complex I) subunit
ATP Synthase Delta (Complex V) subunit
Cytochrome C Oxidase (Complex IV) subunit
NADH dehydrogenase (Complex I) subunit
Cytochrome C Oxidase (Complex IV)subunit
NADH dehydrogenase (Complex I) subunit
NADH dehydrogenase (Complex I) subunit
Quinone dehydrogenase (Complex II) subunit
NADH dehydrogenase (Complex I) subunit
NADH dehydrogenase (Complex I) subunit
NADH dehydrogenase (Complex I) subunit
NADH dehydrogenase (Complex I) subunit
Mitochondrial fission 1 protein
NADH dehydrogenase (Complex I) subunit
Thioredoxin-2
NADH dehydrogenase (Complex I) subunit
Cytochrome C1
Cytochrome B5R3
Cytochrome b-c1 complex subunit 1
Cytochrome b-c1 complex subunit 1
Ser/Thr kinase (Mito. Clearance-Autophagy)
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TABLE V: Altered Genes Important for TLR-Type I IFN Signaling in Naïve RKIP-/- B Cells
Relative Expression
Wild Type

RKIP-/-

log2 (Fold Change)

p-value

Pattern Recognition Receptors
Tlr1
Chr. 5
Tlr2
Chr. 3
Tlr3
Chr. 8
Tlr4
Chr. 4
Tlr5
Chr. 1
Tlr6
Chr. 5
Tlr7
Chr. X
Tlr8
Chr. X
Tlr9
Chr. 9
Tlr11
Chr. 14
Tlr12
Chr. 4
Tlr13
Chr. X
Ddx58 (RIG-I)
Chr. 4
Ifih1 (MDA-5)
Chr. 2

16.27
1.16
0.80
1.70
0
1.29
3.61
0.63
0.82
0.28
1.04
0.11
7.50
1.16

9.27
1.00
0.25
1.33
0.02
0.85
2.69
0.21
0.13
0.09
0.69
0.05
4.66
0.85

-0.811
-0.022
-1.691
-0.355
N.A.
-0.595
-0.423
-1.597
-2.71
-1.597
-0.597
-1.013
-0.685
-0.453

0.0514
0.7594
0.0478*
0.5374
0.2244
0.4243
0.3728
0.1165
0.0121*
0.2275
0.4232
0.5050
0.1002
0.4220

Type I IFN Generation
Mavs (IPS-1)
Tmem173 (STING)
Ticam1 (TRIF)
Tram
Tank
Ikbke (IKKε)
Traf3
Tbk1
Irf3
Irf7

Chr. 2
Chr. 18
Chr. 17
Chr. 1
Chr. 2
Chr. 1
Chr. 12
Chr. 10
Chr. 7
Chr. 6

13.95
52.65
7.68
21.09
28.27
1.64
2.29
9.40
5.27
7.48

8.81
32.02
2.49
15.14
18.77
0.48
0.78
5.45
1.45
1.96

-0.663
-0.714
-1.626
-0.478
-0.591
-1.789
-1.562
-0.787
-1.862
-1.925

0.1293
0.0771
0.0009***
0.2392
0.2103
0.0180*
0.0026**
0.0675
0.0027**
0.0018**

Type I IFN Signaling
Ifnar1
Ifnar2
Stat1
Stat2
Stat3
Irf9
Cxcl9
Cxcl10
Cxcl11

Chr. 16
Chr. 16
Chr. 1
Chr. 10
Chr. 11
Chr. 14
Chr. 5
Chr. 5
Chr. 5

5.86
3.78
35.29
3.99
10.97
24.59
0.69
0.23
0.30

2.46
2.03
33.29
3.16
6.52
20.98
1.71
1.21
0

-1.256
-0.899
-0.084
-0.338
-0.751
-0.229
1.321
2.419
N.A.

0.0030**
0.2210
0.8486
0.4458
0.1160
0.5877
0.0669
0.2228
0.1349

Gene

Location
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TABLE V: Altered Genes Important for TLR-Type I IFN Signaling in Naïve RKIP-/- B Cells
Relative Expression
Gene
Type I Interferons
Ifna4
Ifna5
Ifna13
Ifna14

Location

Wild Type

RKIP-/-

log2 (Fold Change)

p-value

Chr. 4
Chr. 4
Chr. 4
Chr. 4

0
0.53
0.45
0.53

0.22
0.18
0.61
0.18

N.A.
-1.556
0.436
-1.556

0.1421
0.4870
0.7858
0.4870

† Ifna1,2,6,7,9,11,12 Ifnb, Ifne, Ifnk, Ifnz – Not Detectable
MyD88 & NF-κB Signaling
Myd88
Chr. 9
Cd14
Chr.18
Ly96 (MD-2)
Chr. 1
Tollip
Chr. 7
Tirap
Chr. 9
Irak1
Chr. X
Irak4
Chr. 15
Irak3 (IRAK-M)
Chr. 10
Traf2
Chr. 2
Traf6
Chr. 2
Map3k7 (TAK-1)
Chr. 4
Ripk1 (Rip1)
Chr. 13
Map3k8 (Tpl2)
Chr. 18
Irf5
Chr. 6
Chuk (IKKα)
Chr. 19
Ikbkb (IKKβ)
Chr. 8
Ikbkg (IKKγ)
Chr. X
Nfkbia (IκBα)
Chr. 12
Rela
Chr. 9
Relb
Chr. 7
Nfkb1 (p105)
Chr. 3
Mapk11 (p38)
Chr. 15
Mapk8 (JNK)
Chr. 14
Mapk1 (ERK)
Chr. 16

10.39
0.63
9.34
6.72
1.99
9.55
8.32
2.75
31.54
3.41
2.08
3.32
16.42
78.11
4.95
21.97
6.96
73.79
25.45
9.15
19.88
19.37
0.74
8.99

4.39
0.58
3.67
3.50
1.24
4.81
4.52
1.40
14.50
1.55
0.98
1.84
7.41
32.38
2.81
8.03
2.27
38.71
8.12
2.35
12.63
7.72
0.95
7.15

-1.237
-0.130
-1.349
-0.939
-0.685
-0.989
-0.881
-0.978
-1.122
-1.135
-1.095
-0.874
-1.147
-1.27
-0.814
-1.453
-1.615
-0.931
-1.648
-1.961
-0.931
-1.327
0.345
-0.329

0.0100**
0.9053
0.0813
0.0330*
0.2038
0.0268*
0.0479*
0.0956
0.0058**
0.0104*
0.0507*
0.0742
0.0067**
0.0017**
0.1571
0.0011**
0.0057**
0.0217*
7.37x10-5****
0.0002***
0.0217*
0.0017**
0.5689
0.4998

1.73
0.72
0
4.24

1.16
0.30
0.46
2.74

-0.652
-1.265
N.A.
-0.629

0.8053
0.354
0.0649
0.4125

TLR Signaling Effector Molecules
Tnf
Il1b
Il6
Il18

Chr. 17
Chr. 2
Chr. 5
Chr. 9
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TABLE V: Altered Genes Important for TLR-Type I IFN Signaling in Naïve RKIP-/- B Cells
Relative Expression
Gene

Location

Wild Type

RKIP-/-

log2 (Fold Change)

p-value

0
1.76
32.54
41.72
0.14
8.89

N.A
-1.439
-0.329
-1.29
N.A.
-0.482

0.1110
0.1234
0.4760
0.0032**
0.1122
0.2510

TLR Signaling Effector Molecules (cont.)
Ccl3
Ccl4
Ccl5
Cd40
Cd80
Cd86

Chr. 11
Chr. 11
Chr. 11
Chr. 2
Chr. 16
Chr. 16

0.34
4.76
40.88
101.90
0
12.41
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TABLE VI: Normalization of TLR-Type I IFN Genes after TLR Stimulation in RKIP-/- B Cells
Naïve
Gene

Relative
Expression†

LPS

CpG-B

Relative
Expression

p-value

Relative
Expression

p-value

0.0009***
0.0026**
0.0027**
0.0017**
0.0018**
0.0030**
0.0100**
0.0268*
0.0479*
0.0330*
0.0104*

1.2291
1.9121
1.1941
1.7642
1.3720
1.3177
1.7144
1.3225
1.0666
1.2484
0.9545

0.4559
0.0646
0.6824
0.0020**
0.4717
0.1425
0.0497*
0.1372
0.7417
0.3048
0.8360

0.9894
1.5892
0.8029
0.8705
0.2994
0.9030
0.9104
1.1498
1.0336
1.2885
1.0706

0.9506
0.02292*
0.4315
0.3145
3.15x10-6****
0.4149
0.5036
0.3525
0.8596
0.0491*
0.6418

0.0514
0.7594
0.0478*
0.5374
0.4243
0.3728
0.1165
0.0121*
0.2275
0.4232
0.505
0.1002
0.422

1.2171
0.6973
0.4643
1.9635
1.9506
1.2270
0.5362
0.2140
1.1618
0.4879
0.1019
1.0943
0.7829

0.3111
0.4475
0.2138
0.1049
0.3076
0.5047
0.2191
0.2839
0.8494
0.2162
0.9291
0.6178
0.3916

0.9046
0.7145
1.0053
0.6574
0.7490
1.0651
0.6558
1.3147
2.3016
1.0521
0.3042
0.5187
0.8742

0.5155
0.3626
0.2777
0.4839
0.3350
0.7718
0.7780
0.6933
0.3307
0.9385
0.2380
0.1972
0.6581

p-value

TLR-Type I IFN Signaling Genes
Ticam1 (TRIF)
Traf3
Irf3
Irf5
Irf7
Ifnar1
Myd88
Irak1
Irak4
Tollip
Traf6

0.3242
0.3406
0.2751
0.4145
0.2620
0.4198
0.4225
0.5037
0.5434
0.5208
0.4545

Pattern Recognition Receptors
Tlr1
Tlr2
Tlr3
Tlr4
Tlr6
Tlr7
Tlr8
Tlr9
Tlr11
Tlr12
Tlr13
Ddx58 (RIG-I)
Ifih1 (MDA-5)

0.5699
0.9848
0.3097
0.7818
0.6620
0.7458
0.3305
0.1528
0.3305
0.6611
0.4955
0.6220
0.7305

†Relative expression of gene of interest in RKIP-/- B cells vs. Wild Type (WT = 1)
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CHAPTER 6

DISCUSSION: RKIP IS AN IMPORTANT, CO-EVOLVED REGULATOR OF
INTERFERON RESPONSES AND MAY PROVIDE A NOVEL TARGET FOR
INTERVENTIONAL CYTOKINE-BASED THERAPY
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INTRODUCTION
The preceding studies have defined, for the first time, important roles for RKIP within the
immune system. RKIP’s primary immunological function is to facilitate cytokine responses from
T cells and APCs after stimulation through the TCR and PRRs respectively, and has a
particularly important role in driving the production of Type-I and Type-II interferons.
Additionally, we identify RKIP’s requirement for the development of competent Tc1 effectors in
a mouse model of systemic inflammatory response syndrome, as well as, its place in providing
appropriate adjuvant responses in B cells, specifically to nucleic acids. Finally, we also establish
that RKIP is a druggable protein, and through its targeted inhibition, cytokine responses can be
greatly attenuated. This highlights locostatin as a new potential therapeutic intervention for
inflammatory diseases that involve the overproduction of interferons, including SIRS, SLE, RA,
and others. In this final chapter, I will discuss our current working molecular hypothesis for
RKIP’s role in Type-I IFN synthesis, as well as its impact in interferon signaling for the immune
system at large. Also, I will outline a hypothesis for how RKIP came to be an important regulator
of IFN signaling involving viral evasion and co-evolution. This will be followed by a discussion
of the future directions that need to be accomplished in order to determine RKIP’s exact
molecular mechanism for its immunological function, and what disease models should be tested
to provide the best evidence for future translational studies. Finally, I will finish with brief
speculation on how locostatin may be used in the clinical setting as a novel treatment modality
for cytokine-based therapeutic strategies.
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RKIP DRIVES TYPE-I INTERFERON RESPONSES AFTER NUCLEIC ACID
SENSING: A WORKING MODEL
Prior to TLR ligation, RKIP is most likely bound to Raf-1 preventing the downstream signaling
of the Raf-MEK-ERK axis. This was the initially defined by Yeung. et. al. in 1999, that RKIP
interacted with Raf-1 as evidenced by their co-immunoprecipitation and co-localization with one
another by confocal microscopy. This interaction is fairly high affinity (~KD= 11±3 μM in
humans (262) and ~KD=20μM in rats (263); however, no studies to our knowledge have been
done in vivo to determine RKIP’s relative affinity for Raf-1 versus other potential ligands.
Additionally, it is not known if the default binding of RKIP to Raf-1 observed in cancer cell lines
remains true for all cell types, or whether this translates in vivo. However, our studies do indicate
that RKIP does inhibit the phosphorylation of ERK, evidenced by an increase in p-ERK when
RKIP is knocked out or is inhibited with locostatin (Fig. 4-1C/D, 5-2A). This increases the
likelihood of this RKIP-Raf interaction being the default state of the cell.
After B cells are exposed to Poly I:C, it is recognized by either endosomal TLR3 or cytosolic
MDA-5, both of which are known to bind long dsRNA like Poly I:C (264, 265). It is unknown
which of these is the predominantly activated pathway in B cells. TLR3 expression is very low in
this population (and even lower in RKIP-/- B cells; Table V), even though it does retain its ability
to signal (266). These pathways may be cooperatively activated (267), but would require
mechanistic studies in Tlr3-/-, Ticam1-/-, or Ifih1-/- mice to determine definitively. Once Poly I:C
ligates its corresponding PRR, downstream signaling results in the K-63 poly-ubiquitylation of
TRAF3, which prevents its proteosomal degradation (268, 269). Subsequently, TRAF3 forms a
critical signaling complex consisting of itself, TBK1, and IKKε which is responsible for
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phosphorylation of IRF3 and IRF7 (270-272). These IRFs act as transcription factors (either
homo- or heterodimers) that lead to Type-I IFN production (273).
Because inhibition or genetic loss of RKIP results in significantly attenuated levels of IFNα
production after Poly I:C stimulation (Fig. 5-3D, 5-8A/B), one possibility is that RKIP acts to
provide stability to this critical TRAF3/TBK1/IKKε complex, perhaps acting as a scaffold
protein (Figure 6-1, (1)). The change in affinity away from Raf-1 and towards this complex, most
likely requires a post-translational modification. Protein kinase C is known to phosphorylate
RKIP which causes an affinity shift from Raf-1 to GRK2 (212). There is additional evidence that
RKIP phosphorylation results in dimer formation which may also be responsible for alterations
in affinity (274) towards non-Raf targets. Irrespective of the mechanism by which RKIP gains
affinity for the TRAF3/TBK1/IKKε complex, a critical RKIP-mediated effect on this complex is
a very plausible hypothesis given that locostatin can inhibit both early transcription and
translation of the Ifna gene.
RKIP inhibition also leads to an even more pronounced reduction in IFNα during the feedforward phase of the reaction. This phase is critical for mediating robust immune responses to
viruses and vaccine adjuvants (275), as well as resultant pathology in systemic autoimmunity
(276, 277). The mechanism that mediates this enhancement is typically through increased
coupling of the receptor to downstream signaling molecules. This usually occurs at the level of
increased recruitment of small molecule adaptors, such as TYK2 or JAK1 in the case of IFNAR,
to the receptor. These facts give way to another possibility that could account for the decreased
IFNα production in the response to Poly I:C, namely that RKIP could be responsible for
maintenance of the feed-forward phase of the response by facilitating the recruitment of these
adaptor molecules to IFNAR (Figure 6-1, (2)). This hypothesis doesn’t account for decreased
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IFNα production in the early phase; however, this may also be explained by the need for
functional RKIP in the maintenance of appropriate basal circulating levels of TRIF-Type-I IFN
signature transcripts (Fig. 5-7A).
Based on the two working hypotheses presented above, the mechanism for locostatin inhibition
of IFNα production in wild type B cells may be through the destabilization of the
TRAF3/TBK1/IKKε complex as RKIP is prevented from binding, or through abolishment of the
ability of IFNα to feed-forward through IFNAR ligation (Figure 6-1, right panel). The exact
mechanism of this inhibition will require identification if locostatin is to be used clinically.
ESTABLISHING RKIP’S ROLE WITHIN THE IMMUNE RESPONSE
Type-I IFNs can elicit pleiotropic effects after ligation of their receptor, IFNAR (Figure 6-2).
IFNAR is expressed on nearly every cell in the body at different levels, and the response that is
generated after Type-I IFN signaling depends on the cell’s identity, as well as the relative
expression of different STAT proteins within the cell (278). This makes the true nature of the
Type-I IFN response within the immune system, and the body at large, exceedingly complex.
Through RKIP’s ability to facilitate Type-I IFN production, it is able to affect many different
areas of both the innate and adaptive immune response. First, after stimulation with nucleic acid
patterns, APCs respond to Type-I IFNs through autocrine or paracrine signaling which leads to
an up-regulation of PRRs, including TLR3 and TLR7, as well as increases in anti-viral response
genes (279) and APC maturation (280) through the phosphorylation of STAT-1/2 heterodimers.
Also, in B cells specifically, Type-I IFNs can elicit increases in survival due to up-regulation of
BAFF and APRIL (281, 282), as well as promote antibody production of T cell-independent
antigens (283). Because nearly every successful vaccine used in clinical medicine utilizes the
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production of antibody, RKIP may be an essential player in this process, especially with the use
of nucleic acid adjuvants on the rise.
RKIP may also impact the ability to establish proper chemokine gradients, which are driven by
Type-I IFN autocrine signaling to APCs and paracrine signaling on tissue mesenchymal cells.
This is driven by the p-STAT-1/2 and IRF9 (ISGF3) trimeric complex binding to interferonsensitive response elements (ISREs) in the enhancer regions of Cxcl9/10/11 which recruit
activated neutrophils and T cells via CXCR3 (284, 285). This response is also enhanced by
Type-I IFN mediated IFNγ production which can also drive CXCL9/10/11 synthesis by p-STAT1/1 binding of IFNγ-activating (GAS) sites within the enhancer regions of these genes (286,
287). Type-I IFN can also drive production of CCL2/7 which induce recruitment and proinflammatory responses from macrophages and Tip-DCs (288, 289). In preliminary studies, we
observed altered migration to liver of adoptively transferred TCR-transgenic T cells after
immunization in RKIP-/- recipients, suggesting that RKIP may indeed be necessary for
establishing specific chemotactic gradients.
Through the studies presented in chapter 3, we established the importance of RKIP for the proper
differentiation of Tc1 effector CTLs, as well as their ability to produce the effector cytokine,
IFNγ, after TCR triggering (Fig. 3-1, 3-5). We determined that this was due, at least in part to an
intrinsic defect downstream of the TCR signaling apparatus in Tc1 T cells devoid of RKIP (Fig.
3-7). However, Type-I IFNs have been shown to directly affect the production of Type-II IFN,
IFNγ, through the phosphorylation of STAT-4 homodimers after IFNAR ligation in Th1 and Tc1
T cells, as well as natural killer (NK) cells (290-293). Type-I IFNs can also drive IFNγ
production through the IL-12 independent differentiation of CD4+ Th1 T cells, which provide
help to developing CD8+ Tc1 effectors (294-296), in addition to augmenting proliferation and
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memory formation (297) of CD8+ T cell directly (298-300). To sum, the data in this thesis imply
that RKIP may be responsible for coupling the cooperative generation of Type I and Type II
IFNs during the immune response. The importance of this RKIP-mediated regulation is
evidenced by the fact that RKIP seems to control the production of IFNγ at several different
levels of the reaction including: the synthesis of Type-I IFN, the skewing of Th1 helper T cells,
the differentiation of Tc1 effectors per se, and the direct control over IFNγ after TCR triggering
in these cells.
Finally, RKIP may be involved in several suppressive immunoregulatory effects of Type-I IFNs.
Previously, Type-I IFN signaling has been shown to cause phosphorylation of STAT-3
homodimers in certain cell types, such as T regulatory cells (Tregs) and anti-inflammatory
macrophages (301, 302). Also, LPS can drive the production of IL-10 from both mouse (303)
and human (304) PBMCs through a mechanism that is dependent on Type-I IFN. A controversy
still remains to whether the exact signaling machinery required for this effect is direct
transcription of the Il10 gene by p-STAT-3 (46), or through indirect activation of the PI3K-AktmTOR axis by JAK1 after IFNAR ligation (305). Recently, a new subtype of T regulatory cell,
characterized by the transcription factor FoxA1, has been implicated in relapsing-remitting
multiple sclerosis patients and in experimental autoimmune encephalomyelitis as a mechanism
for symptom abatement after IFNβ administration. These Tregs were shown to suppress by pSTAT3 mediated up-regulation of programmed cell death ligand 1 (PD-L1), which was driven
by exposure to Type-I IFN (306, 307). Because RKIP may be involved in both pro-inflammatory
and anti-inflammatory processes through the actions of Type-I IFN, it will require significant
future studies in order to determine the exact balance of these facets in different clinical contexts.
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Only through these studies will it be possible to accurately predict which clinical scenarios
would potentially benefit from inhibition of RKIP function.

THE GREAT ARMS RACE: VIRAL EVASION, INTERFERONS, AND RKIP COEVOLUTION
Darwinian evolution is the ultimate driving force behind biological diversity, fitness, and
survival. Nothing exemplifies this concept better that the ongoing evolutionary “arms race”
between pathogens and their hosts. The immune system has evolved numerous mechanisms, both
specific and redundant, that aim to prevent, control, and eliminate infection by pathogens.
Analogously, pathogens utilize inefficient genomic replication systems to allow evolution,
through enhanced mutation rates, to happen on an abbreviated time scale. The outcome of this
process, in many cases, is an increased level of fitness and survivability through the development
of mechanisms that allow for immune system subversion or circumvention.
Viruses, because of their significant diversity and ability to rapidly evolve, present a unique
challenge to the host’s immune system (308). One of the most evolutionarily conserved
mechanisms for eliciting anti-viral control is the Type-I IFN response. They were initially
discovered by work done in the 1950s from Nagano and Kojima (309-311), and later Isaacs and
Lindenmann (312), which described novel molecules that inhibited the replication of smallpox
and influenza virus respectively. The exact molecular mechanisms by which IFNs elicit anti-viral
immunity have been reviewed in depth previously (313), and seem to be conserved in most
vertebrates (314) including humans (315), as far back as bony fish (Osteichthyes) (316).
However, they have not yet been detected in invertebrate species. The importance of type-I IFN
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mediated control of viral pathogens is illustrated by two critical facts: 1) mice and humans that
have deficiencies in IFN production or signaling have increased morbidity and mortality to
viruses (317), and 2) viruses have evolved mechanisms to subvert the IFN response at nearly
every level (308). These viral subversion techniques include sequestration of viral dsRNA from
nucleic acid sensing PRRs by Ebola virus-VP35 (318), Vaccinia virus-E3L (319), and Influenza
A virus-NS1 (320), degradation or cleavage of TRIF and IPS-1 by Hepatitis C virus-NS3-4A
(321), or disruption of signaling machinery through direct inhibition (e.g. Hepatitis C virusNS5A (322, 323) and NS3-4A (324), Ebola viru-VP35 (318), Vaccinia virus-E3L (325) and
A52R (326), and Influenza A virus-NS1 (327). These methods to circumvent viral immunity are
just a few examples to highlight how extensively the IFN pathway can be attenuated by viral
proteins.
By analyzing which host proteins are targeted by viral factors, new innate immunological
functions can be ascribed to poorly-defined host proteins, or can even lead to the discovery of
new proteins. In 2011, Folly and colleagues demonstrated by two-hybrid technology that the
PrM structural protein from the human pathogen Dengue-2 virus physically interacted with the
human form of RKIP (PEBP-1) (328). The authors go on to posit: “As induction of [the] IFNalpha gene family is dependent on IRF7, it is formally possible that the PrM-RKIP (PEBP)
complex might be inhibiting TAK1/IKK-dependent phosphorylation of the TLR3/7 receptors,
negating the expression of IFN-alpha and therefore, IFN-alpha dependent genes.” To the best of
our knowledge, our studies involving RKIP are the first to demonstrate experimentally that this
hypothesis may have a high likelihood of being correct. Although future studies are required to
determine the exact mechanism by which RKIP facilitates IFNα production, after these data are
obtained, the purpose of PrM’s interaction with RKIP in humans should be easily extrapolated.
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These findings, in the context of our work, strongly implicate RKIP as molecule that has coevolved alongside IFNs and nucleic acid sensors in order to mediate these interferon responses
and facilitate anti-viral immunity.

FUTURE DIRECTIONS
The current studies described herein have begun to highlight the role that RKIP plays in
mediating interferon responses within the immune system. Although our knowledge of RKIP’s
function in the context of in vitro and in vivo immunity have grown exponentially through this
work, there are still significant strides to be made in terms of establishing both the exact
molecular mechanism by which it functions in these responses, as well as if or how these
findings translate into a broader range of in vivo disease models and human immunity.
Currently, in order to better elucidate a molecular mechanism for how RKIP drives Type-I IFN
production in APCs, we plan to explore what proteins RKIP co-localizes with after Poly I:C
stimulation by confocal microscopy. Based on our cytokine and transcriptome studies, the list of
potential RKIP binding partners is small enough to utilize this approach. We already have a
commercially available FITC conjugated anti-RKIP antibody that works well for indirect
immunofluorescence (Fig. 4-4A) which should be applicable for confocal microscopy as well.
Also, antibodies for microscopy are commercially available for nearly all of our potential target
proteins including TRAF3, TBK1, IKKε, IFNAR, JAK1, and TYK2. Unfortunately conventional
co-immunoprecipitation of RKIP from primary cells is currently hampered by a lack of reagents
that can bind RKIP for immunoprecipitation. RKIP can be immunoprecipitated from cell lines
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after transfection of tagged-RKIP; however, the relevancy of this approach is unclear, given our
interest in RKIP’s interaction in vivo, or at the very least, in primary immune cells.
After we establish the binding partners of RKIP in our model, the next question we will seek to
answer is whether or not these interactions can be destabilized by the irreversible inhibition of
RKIP by locostatin. Because RKIP is covalently modified by locostatin within its ligand binding
pocket (172), theoretically this should prevent RKIP from interacting with other proteins. An
observable destabilization of the RKIP containing complex could then be linked to decreased
IFNα production after RKIP blockade. This could be accomplished experimentally, once again
through imaging by confocal microscopy, or by gel filtration. Additionally, we will seek to
confirm our attenuated TRIF-Type-I IFN transcriptomic signature at the protein level by mining
of the wild type and RKIP-/- proteomes by PF-2D proteomics (Figure 6-3). Through this
approach we can not only confirm the identity of altered proteins within these specific signaling
pathways, but also uncover new putative targets affected by RKIP during PRR signaling in
APCs.
Finally, the breadth of potential clinical applicability of RKIP inhibition can be tested by
locostatin therapy in different disease models. This allows for the circumvention of caveats that
arise when using knockout mouse models. We have already established a potential role for RKIP
modulating IFNγ production from Tc1 effectors in a mouse model of SIRS; however, given the
evidence presented in chapter 5, we must now expand to models that are affected by altered
production of Type-I IFN including: SLE, IBD, Psoriasis, MS, viral infection, and hematologic
malignancy. The rationale for studying these diseases will be discussed at length in the next
section.
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LOCOSTATIN: A NEW CYTOKINE-BASED THERAPEUTIC INTERVENTION?
The clinical relevancy of these studies centers on the ability to utilize RKIP-inhibition by the
small molecule inhibitor locostatin as a potential therapeutic intervention to treat human
inflammatory diseases which consist of dysregulated interferon responses as part of their
pathogenesis. Locostatin has the potential to provide therapeutic benefits over many current
forms of treatment. First, because locostatin is a small organic molecule, it has the potential to be
formulated for use per os, as most oxazolidinones have adequate oral bioavailability (329). This
would provide a tremendous advantage to conventional monoclonal antibody biologics which are
given by intravenous infusion or subcutaneous injection (330). Second, based on our studies of
locostatin, it seems that it would fall in the middle of the spectrum in terms of
immunosuppressive potency, of which either extreme could be disadvantageous. For example,
the most common treatment for intense inflammatory reactions is corticosteroids which cause
very robust immunosuppression, leaving the patient susceptible to opportunistic infections. In
chapter 3, we show that despite the defect seen in IFNγ from CD8+ T cells, these cells were still
able to respond with cytokine production in response to a TLR stimulus such as LPS (Fig. 3-10).
This suggests that patients may still be able to respond normally to pathogenic invasion, even
under RKIP-inhibition. On the other hand, in contrast to most modern anti-cytokine based
interventions, locostatin may provide a slightly broader suppressive response compared to the
inhibition of one particular cytokine, given its ability to affect Type-I and Type-II IFNs, as well
as interferon-stimulated cytokines like CCL2 and CXCL10.
The most likely clinical scenarios where locostatin therapy would have potential benefits are
diseases that have established pathogenic connections to dysregulated Type-I or Type-II
interferon responses. These include: SIRS, which was discussed at length in chapter 3, systemic
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lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD),
psoriasis, coeliac disease, and multiple sclerosis (MS). In SLE, patients have abnormally high
levels of IFNα in their serum (331, 332), as well as genes involved in the “Type-I IFN signature”
(255, 333). Serum from these patients was able to induce APC maturation (increased MHC-II
and the con-stimulatory molecules CD80/CD86) and differentiation of antibody secreting plasma
cells (334). Additionally, some patients that have received recombinant IFNα therapy for
hepatitis C infection have developed an SLE-like syndrome with the production of anti-nuclear
antibodies (ANA) (335). Phase-I clinical trials have been conducted using anti-IFNα neutralizing
antibodies which have shown some improvement in symptomology (334); however, it may prove
to be more beneficial to block IFNα production rather than blocking its effects post hoc.
Similarly, psoriasis and coeliac disease both exhibit exacerbation of symptomology in the
presence of type-I IFN. In a xenograft model of psoriasis, development of skin lesions and
activation of autoreactive T cells could be inhibited through the suppression of IFN signaling
through IFNAR blockade (336) or anti-BDCA2 (337), which prevents IFNα production from
pDCs. Th1 polarization, robust IFNγ synthesis and presentation of gluten specific peptides to
autoreactive T cells is the main driving force behind the pathology seen in coeliac patients (338,
339). However, anti-IFNα treatment of biopsy specimens from coeliac patients was able to
inhibit IFNγ production (340), the mechanism of which has been discussed previously.
On the other hand, diseases that have their pathology related to mixed Th1/Th17 responses, such
as MS, RA, and IBD, are much more controversial in regard to their response to Type-I IFN
inhibition. In MS, IFNβ (Betaseron) is prescribed as fairly efficacious therapeutic option (341),
and in mouse models of MS such as EAE, IFNβ deficient mice develop worse disease (342), but
can be improved with analogous IFNβ administration (343). Also, Type-I IFNs have been shown
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to inhibit Th17-mediated inflammation in EAE (344), suggesting that the therapeutic action of
IFNβ administration may be through both Th17 suppression and induction of FoxA1+ Tregs (Fig.
6-2). Similarly, treatment with interferons in both the collagen induced arthritis model of RA
(345) and human IBD patients (346-348) have shown promising results. However, because each
of these three diseases are also impacted by a significant Th1 component and Type-I IFNs are
known to drive these responses, it remains an exceptionally complex system to treat, which may
provide insight into why some recombinant IFN therapies have exhibited contradictory results
(349-351). Irrespective of existing experimental evidence in humans and mouse disease models,
locostatin-mediated inhibition of IFNα and IFN-stimulated genes must be tested individually in
each disease model in order to determine experimentally the effectiveness of this therapeutic
strategy.
CONCLUSIONS
The studies presented herein were designed to test if Raf-1 kinase inhibitor protein (RKIP)
played any functionally significant role in immunity, and to interrogate its possibility of
providing a novel therapeutic target for modulating inflammatory responses. Based on previous
studies from other laboratories that attributed negative regulatory functions to RKIP in the
context of MAPK and NF-κB signaling in cell lines, we set out with the hypothesis that its
function was to suppress the production of pro-inflammatory cytokines, proliferation, and cell
survival. However, after extensive investigation, our data clearly demonstrate that RKIP is
actually necessary for the production of certain cytokines, namely Type-I and Type-II
interferons, but was less involved in cell survivability and proliferation. Additionally, this work
has established RKIP as an important contributor to the signaling machinery downstream of TCR
triggering in CD8+ T cells and TLR ligation in APCs. Finally, these studies have shown that
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RKIP is a druggable protein, and through its targeted inhibition, cytokine responses can be
significantly diminished. Thus, this provides elementary rationale for its potential clinical
applicability in therapeutic interventions for inflammatory diseases (Figure 6-4). Through this
current work, we have provided a solid foundation for future studies that seek to investigate
further the molecular mechanisms of RKIP function within the immune system, as well as its
advancement into clinically relevant inflammatory disease models.
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Figure 6-1: Working model of RKIP’s functional role in mediating Type-I IFN production
from APCs after Poly I:C stimulation (Left Panel) Prior to stimulation, RKIP is bound to Raf1, thus preventing its phosphorylation of MEK and keeping MAPK activity suppressed.
Signaling machinery for TRIF-TRAF3-IRF axis, NF-κB, and signaling through IFNAR is
synthesized, but not held in a functional confirmation thus preventing the synthesis of cytokines.
(Center Panel) After Poly I:C administration, the dsRNA is sensed either through ligation of
TLR3 in endosomes, binding to MDA-5 in the cytosol, or through the production of cyclic-diGMP and activation of ER-associated STING. These events (along with IL-1R signaling) lead to
the K-63 mediated poly-ubiqutinylation of TRAF3 and prevents its proteasomal degradation.
TRAF3 subsequently binds to IKKɛ and TBK-1 to facilitate phosphorylation of IRF3 and IRF7
which translocate to the nucleus driving the production of Type-I IFNs. These Type-I IFNs act in
an autocrine (or paracrine) fashion through IFNAR ligation which leads to phosphorylation of
STAT1/2 heterodimers, and with the aid of IRF9, drives the expression of IFN-responsive genes
such as CXCL10 by binding interferon-stimulated response elements (ISRE). After exposure to
Poly I:C, RKIP may become post-translationally modified, and lose affinity for Raf-1 while
gaining affinity for other proteins, thus allowing the formation of the transcription factor AP-1,
in concert with NF-κB signaling, which drives a pro-inflammatory and co-stimulatory genetic
program. RKIP also facilitates the production of Type-I IFNs, perhaps through direct
stabilization of complexes upstream of IRF phosphorylation (1), or aiding in receptor coupling of
IFNAR to its downstream elements, thus enhancing the necessary IFN feed-forward loop (2).
(Right Panel) Treatment with the RKIP inhibitor locostatin significantly attenuates the Type-I
IFN response, potentially through the destabilization of upstream signaling complexes or
uncoupling of the IFNAR receptor.
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Figure 6-2: RKIP is necessary for maintenance of interferon-mediated effector functions in
immune cells Through these studies, we have determined that RKIP imparts positive effects on
both Type I and Type II IFNs. First, RKIP is necessary for the generation of CD8+ Tc1 CTL
effectors and proper production of their effector cytokine, IFNγ, during serial-TCR triggering.
The exact molecular mechanism of this effect requires further study, however, it is clear that
RKIP is most likely involved downstream of the TCR machinery. Additionally, RKIP is also
necessary for the appropriate production of Type-I IFNs during sensing of nucleic acid PAMPs
in APCs. This attenuated response in situations where RKIP function is inhibited can have widereaching effects, given the pleiotropic nature of Type-I IFN function including: an indirect effect
on IFNγ production from Th1, CTLs, and NK cells through decreased STAT4 phosphorylation,
decreased CXCR9/10-mediated chemotactic gradients, potentially attenuated anti-viral
responses, and a worsening of some autoimmune diseases, such as multiple sclerosis, due to a
decrease in FoxA1+ Tregs expressing PD-L1. Nevertheless, the fact that RKIP can be inhibited
using the small molecule inhibitor locostatin opens the door to future therapeutic interventions in
inflammatory diseases that are mediated or potentiated by dysregulated IFN responses including:
SIRS, SLE, RA, coeliac disease, and psoriasis.
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Figure 6-3: Utilizing ProteomeLab PF-2D to mine proteomic changes in RKIP-/- mice
Schematic of workflow and analysis of PF-2D proteomic mapping of naïve wild type and RKIP-/naïve B cells; By using a full proteomic mining approach, we can gain new insight into the
attenuated Type-I IFN transcriptome signature seen in RNAseq at the protein level. Additionally,
we can determine whether transcript normalization after TLR ligation in B cells also normalizes
the proteome. Finally, given that the PF-2D platform can also detect post-translational
modifications of proteins by 1st dimensional pI shifts, a careful analysis of “fingerprints” may
allow us to better understand exactly how RKIP imparts its effects in immune cells at the
molecular level.
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Figure 6-4: Avoiding the Tomato Effect: how much evidence is enough in the era of
evidence based medicine? The “Tomato Effect” is a clinical rejection of potentially highly
efficacious therapies due to a poor understanding of the mechanism by which they operate (352).
To avoid this, especially in the era of evidence-based medicine, a significant amount of data
must be obtained from different scientific approaches along a continuum in an effort to provide
enough evidence for translation of a new therapeutic approach to the clinical setting. (Left Panel)
Schematic of the “ideal” points of evidence that should be established in order to provide
adequate scientific rationale for future human studies, ranging from low relevancy, high
reproducibility systems approaches to highly relevant, but low reproducibility human studies;
(Right Panel) The scientific approach utilized and evidence gathered during the current studies
involving the interrogation of RKIP as a potential target for modulating inflammatory responses;
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